{"drug_name": "Aspirin", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 1)", "text": "for the temporary relief of minor aches and pains or as recommended by your doctor. Because of its delayed action, this product will not provide fast relief of headaches or other symptoms needing immediate relief. ask your doctor about other uses for this product", "source": "DailyMed"}
{"drug_name": "Aspirin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 1)", "text": "drink a full glass of water with each dose adults and children 12 years and over: take 4 to 8 tablets every 4 hours not to exceed 48 tablets in 24 hours unless directed by a doctor children under 12 years: consult a doctor", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 1)", "text": "Cardiovascular Thrombotic Events CONTRAINDICATIONS WARNINGS Ibuprofen Oral Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see and ).", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 2)", "text": "Cardiovascular Thrombotic Events CONTRAINDICATIONS WARNINGS Ibuprofen Oral Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see and ). Gastrointestinal Risk • WARNINGS PRECAUTIONS Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 3)", "text": "Cardiovascular Thrombotic Events CONTRAINDICATIONS WARNINGS Ibuprofen Oral Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see and ). Gastrointestinal Risk • WARNINGS PRECAUTIONS Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see and ).", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 4)", "text": "Cardiovascular Thrombotic Events CONTRAINDICATIONS WARNINGS Ibuprofen Oral Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see and ). Gastrointestinal Risk • WARNINGS PRECAUTIONS Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see and ). • CONTRAINDICATIONS WARNINGS Ibuprofen Oral Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see and ).", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 5)", "text": "Gastrointestinal Risk • WARNINGS PRECAUTIONS Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see and ). • CONTRAINDICATIONS WARNINGS Ibuprofen Oral Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see and ). • WARNINGS NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 6)", "text": "This risk may occur early in treatment and may increase with duration of use (see and ). • CONTRAINDICATIONS WARNINGS Ibuprofen Oral Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see and ). • WARNINGS NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 7)", "text": "• CONTRAINDICATIONS WARNINGS Ibuprofen Oral Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see and ). • WARNINGS NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see ).", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 1)", "text": "WARNINGS Carefully consider the potential benefits and risks of Ibuprofen Oral Suspension and other treatment options before deciding to use Ibuprofen Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ).", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 2)", "text": "WARNINGS Carefully consider the potential benefits and risks of Ibuprofen Oral Suspension and other treatment options before deciding to use Ibuprofen Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). In Pediatric Patients, Ibuprofen Oral Suspension is indicated: In Adults, Ibuprofen Oral Suspension is indicated: PRECAUTIONS - Drug Interactions Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended (see ).", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 3)", "text": "WARNINGS Carefully consider the potential benefits and risks of Ibuprofen Oral Suspension and other treatment options before deciding to use Ibuprofen Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). In Pediatric Patients, Ibuprofen Oral Suspension is indicated: In Adults, Ibuprofen Oral Suspension is indicated: PRECAUTIONS - Drug Interactions Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended (see ). • For reduction of fever in patients aged 6 months up to 2 years of age.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 4)", "text": "Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). In Pediatric Patients, Ibuprofen Oral Suspension is indicated: In Adults, Ibuprofen Oral Suspension is indicated: PRECAUTIONS - Drug Interactions Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended (see ). • For reduction of fever in patients aged 6 months up to 2 years of age. • For relief of mild to moderate pain in patients aged 6 months up to 2 years of age.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 5)", "text": "In Pediatric Patients, Ibuprofen Oral Suspension is indicated: In Adults, Ibuprofen Oral Suspension is indicated: PRECAUTIONS - Drug Interactions Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended (see ). • For reduction of fever in patients aged 6 months up to 2 years of age. • For relief of mild to moderate pain in patients aged 6 months up to 2 years of age. • For relief of signs and symptoms of juvenile arthritis.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 6)", "text": "• For reduction of fever in patients aged 6 months up to 2 years of age. • For relief of mild to moderate pain in patients aged 6 months up to 2 years of age. • For relief of signs and symptoms of juvenile arthritis. • For treatment of primary dysmenorrhea. • For relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 1)", "text": "Ibuprofen Oral Suspension is contraindicated in patients with known hypersensitivity to ibuprofen. WARNINGS - Anaphylactoid Reactions PRECAUTIONS - Preexisting Asthma Ibuprofen Oral Suspension should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 2)", "text": "Ibuprofen Oral Suspension is contraindicated in patients with known hypersensitivity to ibuprofen. WARNINGS - Anaphylactoid Reactions PRECAUTIONS - Preexisting Asthma Ibuprofen Oral Suspension should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see and ).", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 3)", "text": "Ibuprofen Oral Suspension is contraindicated in patients with known hypersensitivity to ibuprofen. WARNINGS - Anaphylactoid Reactions PRECAUTIONS - Preexisting Asthma Ibuprofen Oral Suspension should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients (see and ). WARNINGS Ibuprofen Oral Suspension is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see ).", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 2)", "text": "In patients taking ibuprofen or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1-10% of patients are: abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, fluid retention, gastrointestinal experiences (including abdominal pain, bloating, constipation, diarrhea, dyspepsia, epigastric pain, flatulence, heartburn, nausea, vomiting), headaches, increased bleeding time, nervousness, pruritus, rashes (including maculopapular) and tinnitus.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 3)", "text": "In patients taking ibuprofen or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1-10% of patients are: abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, fluid retention, gastrointestinal experiences (including abdominal pain, bloating, constipation, diarrhea, dyspepsia, epigastric pain, flatulence, heartburn, nausea, vomiting), headaches, increased bleeding time, nervousness, pruritus, rashes (including maculopapular) and tinnitus. Additional adverse experiences reported occasionally include: Body as a whole - fever, infection, sepsis Cardiovascular system - congestive heart failure in patients with marginal cardiac function, hypertension, tachycardia, syncope Digestive system - dry mouth, duodenitis, esophagitis, gastric or duodenal ulcer with bleeding and/or perforation, gastritis, gastrointestinal bleeding, glossitis, hematemesis, hepatitis, jaundice, melena, rectal bleeding Hemic and lymphatic system - ecchymosis, eosinophilia, leukopenia, purpura, stomatitis, thrombocytopenia Metabolic and nutritional - weight changes Nervous system - anxiety, asthenia, confusion, depression, dream abnormalities, drowsiness, insomnia, malaise, paresthesia, somnolence, tremors, vertigo Respiratory system - asthma, dyspnea Skin and appendages - alopecia, photosensitivity, sweat Special senses - blurred vision Urogenital system - cystitis, dysuria, hematuria, interstitial nephritis, oliguria/polyuria, proteinuria, acute renal failure in patients with pre-existing significantly impaired renal function Other adverse reactions, which occur rarely are: Body as a whole - anaphylactic reactions, anaphylactoid reactions, appetite changes Cardiovascular system - arrhythmia, cerebrovascular accident, hypotension, myocardial infarction, palpitations, vasculitis Digestive system - eructation, gingival ulcer, hepatorenal syndrome, liver necrosis, liver failure, pancreatitis Hemic and lymphatic system - agranulocystosis, hemolytic anemia, aplastic anemia, lymphadenopathy, neutropenia, pancytopenia Metabolic and nutritional - hyperglycemia Nervous system - convulsions, coma, emotional lability, hallucinations, aseptic meningitis Respiratory - apnea, respiratory depression, pneumonia, rhinitis Skin and appendages - angioedema, toxic epidermal necrosis, erythema multiforme, exfoliative dermatitis, Stevens Johnson syndrome, fixed drug eruption (FDE), urticaria, vesiculobullous eruptions Special senses - amblyopia (blurred and/or diminished vision, scotomata and/or changes in color vision), conjunctivitis, dry eyes, hearing impairment Urogenital - azotemia, decreased creatinine clearance, glomerulitis, renal papillary necrosis, tubular necrosis", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "The toxicity of ibuprofen overdose is dependent upon the amount of drug ingested and the time elapsed since ingestion, though individual response may vary, which makes it necessary to evaluate each case individually. Although uncommon, serious toxicity and death have been reported in the medical literature with ibuprofen overdosage.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 2)", "text": "The toxicity of ibuprofen overdose is dependent upon the amount of drug ingested and the time elapsed since ingestion, though individual response may vary, which makes it necessary to evaluate each case individually. Although uncommon, serious toxicity and death have been reported in the medical literature with ibuprofen overdosage. The most frequently reported symptoms of ibuprofen overdose include abdominal pain, nausea, vomiting, lethargy and drowsiness.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 3)", "text": "The toxicity of ibuprofen overdose is dependent upon the amount of drug ingested and the time elapsed since ingestion, though individual response may vary, which makes it necessary to evaluate each case individually. Although uncommon, serious toxicity and death have been reported in the medical literature with ibuprofen overdosage. The most frequently reported symptoms of ibuprofen overdose include abdominal pain, nausea, vomiting, lethargy and drowsiness. Other central nervous system symptoms include headache, tinnitus, CNS depression and seizures.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 4)", "text": "Although uncommon, serious toxicity and death have been reported in the medical literature with ibuprofen overdosage. The most frequently reported symptoms of ibuprofen overdose include abdominal pain, nausea, vomiting, lethargy and drowsiness. Other central nervous system symptoms include headache, tinnitus, CNS depression and seizures. Metabolic acidosis, coma, acute renal failure and apnea (primarily in very young children) may rarely occur.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 5)", "text": "The most frequently reported symptoms of ibuprofen overdose include abdominal pain, nausea, vomiting, lethargy and drowsiness. Other central nervous system symptoms include headache, tinnitus, CNS depression and seizures. Metabolic acidosis, coma, acute renal failure and apnea (primarily in very young children) may rarely occur. Cardiovascular toxicity, including hypotension, bradycardia, tachycardia and atrial fibrillation, also have been reported.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 6)", "text": "Other central nervous system symptoms include headache, tinnitus, CNS depression and seizures. Metabolic acidosis, coma, acute renal failure and apnea (primarily in very young children) may rarely occur. Cardiovascular toxicity, including hypotension, bradycardia, tachycardia and atrial fibrillation, also have been reported. The treatment of acute ibuprofen overdose is primarily supportive.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 7)", "text": "Metabolic acidosis, coma, acute renal failure and apnea (primarily in very young children) may rarely occur. Cardiovascular toxicity, including hypotension, bradycardia, tachycardia and atrial fibrillation, also have been reported. The treatment of acute ibuprofen overdose is primarily supportive. Management of hypotension, acidosis and gastrointestinal bleeding may be necessary.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 8)", "text": "Cardiovascular toxicity, including hypotension, bradycardia, tachycardia and atrial fibrillation, also have been reported. The treatment of acute ibuprofen overdose is primarily supportive. Management of hypotension, acidosis and gastrointestinal bleeding may be necessary. In cases of acute overdose, the stomach should be emptied through ipecac-induced emesis or lavage.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 9)", "text": "The treatment of acute ibuprofen overdose is primarily supportive. Management of hypotension, acidosis and gastrointestinal bleeding may be necessary. In cases of acute overdose, the stomach should be emptied through ipecac-induced emesis or lavage. Emesis is most effective if initiated within 30 minutes of ingestion.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 10)", "text": "Management of hypotension, acidosis and gastrointestinal bleeding may be necessary. In cases of acute overdose, the stomach should be emptied through ipecac-induced emesis or lavage. Emesis is most effective if initiated within 30 minutes of ingestion. Orally administered activated charcoal may help in reducing the absorption and reabsorption of ibuprofen.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 11)", "text": "In cases of acute overdose, the stomach should be emptied through ipecac-induced emesis or lavage. Emesis is most effective if initiated within 30 minutes of ingestion. Orally administered activated charcoal may help in reducing the absorption and reabsorption of ibuprofen. In children, the estimated amount of ibuprofen ingested per body weight may be helpful to predict the potential for development of toxicity although each case must be evaluated.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 12)", "text": "Emesis is most effective if initiated within 30 minutes of ingestion. Orally administered activated charcoal may help in reducing the absorption and reabsorption of ibuprofen. In children, the estimated amount of ibuprofen ingested per body weight may be helpful to predict the potential for development of toxicity although each case must be evaluated. Ingestion of less than 100 mg/kg is unlikely to produce toxicity.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 13)", "text": "Orally administered activated charcoal may help in reducing the absorption and reabsorption of ibuprofen. In children, the estimated amount of ibuprofen ingested per body weight may be helpful to predict the potential for development of toxicity although each case must be evaluated. Ingestion of less than 100 mg/kg is unlikely to produce toxicity. Children ingesting 100 to 200 mg/kg may be managed with induced emesis and a minimal observation time of four hours.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 14)", "text": "In children, the estimated amount of ibuprofen ingested per body weight may be helpful to predict the potential for development of toxicity although each case must be evaluated. Ingestion of less than 100 mg/kg is unlikely to produce toxicity. Children ingesting 100 to 200 mg/kg may be managed with induced emesis and a minimal observation time of four hours. Children ingesting 200 to 400 mg/kg of ibuprofen should have immediate gastric emptying and at least four hours observation in a health care facility.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 15)", "text": "Ingestion of less than 100 mg/kg is unlikely to produce toxicity. Children ingesting 100 to 200 mg/kg may be managed with induced emesis and a minimal observation time of four hours. Children ingesting 200 to 400 mg/kg of ibuprofen should have immediate gastric emptying and at least four hours observation in a health care facility. Children ingesting greater than 400 mg/kg require immediate medical referral, careful observation and appropriate supportive therapy.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 16)", "text": "Children ingesting 100 to 200 mg/kg may be managed with induced emesis and a minimal observation time of four hours. Children ingesting 200 to 400 mg/kg of ibuprofen should have immediate gastric emptying and at least four hours observation in a health care facility. Children ingesting greater than 400 mg/kg require immediate medical referral, careful observation and appropriate supportive therapy. Ipecac-induced emesis is not recommended in overdoses greater than 400 mg/kg because of the risk for convulsions and the potential for aspiration of gastric contents.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 17)", "text": "Children ingesting 200 to 400 mg/kg of ibuprofen should have immediate gastric emptying and at least four hours observation in a health care facility. Children ingesting greater than 400 mg/kg require immediate medical referral, careful observation and appropriate supportive therapy. Ipecac-induced emesis is not recommended in overdoses greater than 400 mg/kg because of the risk for convulsions and the potential for aspiration of gastric contents. In adult patients the history of the dose reportedly ingested does not appear to be predictive of toxicity.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 18)", "text": "Children ingesting greater than 400 mg/kg require immediate medical referral, careful observation and appropriate supportive therapy. Ipecac-induced emesis is not recommended in overdoses greater than 400 mg/kg because of the risk for convulsions and the potential for aspiration of gastric contents. In adult patients the history of the dose reportedly ingested does not appear to be predictive of toxicity. The need for referral and follow-up must be judged by the circumstances at the time of the overdose ingestion.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 19)", "text": "Ipecac-induced emesis is not recommended in overdoses greater than 400 mg/kg because of the risk for convulsions and the potential for aspiration of gastric contents. In adult patients the history of the dose reportedly ingested does not appear to be predictive of toxicity. The need for referral and follow-up must be judged by the circumstances at the time of the overdose ingestion. Symptomatic adults should be carefully evaluated, observed and supported.", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 1)", "text": "WARNINGS Carefully consider the potential benefits and risks of Ibuprofen Oral Suspension and other treatment options before deciding to use Ibuprofen Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ).", "source": "DailyMed"}
{"drug_name": "Ibuprofen", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 2)", "text": "WARNINGS Carefully consider the potential benefits and risks of Ibuprofen Oral Suspension and other treatment options before deciding to use Ibuprofen Oral Suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). After observing the response to initial therapy with Ibuprofen Oral Suspension, the dose and frequency should be adjusted to suit an individual patient’s needs.", "source": "DailyMed"}
{"drug_name": "Acetaminophen", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 1)", "text": "• for the temporary relief of minor aches and pains due to • for the minor pain from arthritis • and to reduce fever headache muscular aches backache sore throat flu the common cold toothache premenstrual and menstrual cramps", "source": "DailyMed"}
{"drug_name": "Acetaminophen", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "Overdose warning: Taking more than the recommended dose (overdose) may cause liver damage. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222). Quick medical attention is critical for adults as well as children even if you do not notice any signs or symptoms.", "source": "DailyMed"}
{"drug_name": "Acetaminophen", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Acetaminophen", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 2)", "text": "overdose warning do not take more than directed (see ) dose product from the single dose cup the product is packaged in mL=milliliter age dose adults and children 12 years of age and over 20.3 mL (650 mg) every 4 to 6 hours not to exceed 6 doses in a 24-hour period children 6 to under 12 years of age 10.15 mL (325 mg) every 4 hours not to exceed 5 doses in a 24-hour period children under 6 years of age consult a doctor", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 1)", "text": "500 mg Capsule are blue/pink size “0EL” hard gelatin capsule filled with white to off white granular powder and imprinted with “A45” on pink body with black ink.", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 1)", "text": "Amoxicillin capsules are contraindicated in patients who have experienced a serious hypersensitivity reaction (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin capsules or to other β-lactam antibiotics (e.g., penicillins and cephalosporins).", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 1)", "text": "The following are discussed in more detail in other sections of the labeling: Warnings and Precautions (5.1) [see ] Anaphylactic reactions Warnings and Precautions (5.2) [see ] CDAD", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "1 In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms.", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 2)", "text": "1 In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms. Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin .", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 3)", "text": "1 In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures as required. A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms. Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin . Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients.", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 4)", "text": "A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms. Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin . Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria.", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 5)", "text": "Interstitial nephritis resulting in oliguric renal failure has been reported in a small number of patients after overdosage with amoxicillin . Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria. Renal impairment appears to be reversible with cessation of drug administration.", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 6)", "text": "Crystalluria, in some cases leading to renal failure, has also been reported after amoxicillin overdosage in adult and pediatric patients. In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria. Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin.", "source": "DailyMed"}
{"drug_name": "Amoxicillin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 7)", "text": "In case of overdosage, adequate fluid intake and diuresis should be maintained to reduce the risk of amoxicillin crystalluria. Renal impairment appears to be reversible with cessation of drug administration. High blood levels may occur more readily in patients with impaired renal function because of decreased renal clearance of amoxicillin. Amoxicillin may be removed from circulation by hemodialysis.", "source": "DailyMed"}
{"drug_name": "Azithromycin", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 1)", "text": "2 [see Dosage and Administration ( )] Azithromycin tablets are macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.", "source": "DailyMed"}
{"drug_name": "Azithromycin", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 1)", "text": "Azithromycin tablets, USP 250 mg are supplied as white, oblong, biconvex, film-coated tablets containing azithromycin dihydrate, USP equivalent to 250 mg of azithromycin. Azithromycin tablets, USP 250 mg are debossed with “250” on one side. These are packaged in bottles and blister cards of 6 tablets.", "source": "DailyMed"}
{"drug_name": "Azithromycin", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 2)", "text": "Azithromycin tablets, USP 250 mg are supplied as white, oblong, biconvex, film-coated tablets containing azithromycin dihydrate, USP equivalent to 250 mg of azithromycin. Azithromycin tablets, USP 250 mg are debossed with “250” on one side. These are packaged in bottles and blister cards of 6 tablets. Azithromycin tablets, USP 500 mg are supplied as white, oblong, biconvex, film-coated tablets containing azithromycin dihydrate, USP equivalent to 500 mg of azithromycin.", "source": "DailyMed"}
{"drug_name": "Azithromycin", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 3)", "text": "Azithromycin tablets, USP 250 mg are debossed with “250” on one side. These are packaged in bottles and blister cards of 6 tablets. Azithromycin tablets, USP 500 mg are supplied as white, oblong, biconvex, film-coated tablets containing azithromycin dihydrate, USP equivalent to 500 mg of azithromycin. Azithromycin tablets, USP 500 mg are debossed with “500” on one side.", "source": "DailyMed"}
{"drug_name": "Azithromycin", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 4)", "text": "These are packaged in bottles and blister cards of 6 tablets. Azithromycin tablets, USP 500 mg are supplied as white, oblong, biconvex, film-coated tablets containing azithromycin dihydrate, USP equivalent to 500 mg of azithromycin. Azithromycin tablets, USP 500 mg are debossed with “500” on one side. These are packaged in bottles and blister cards of 3 tablets.", "source": "DailyMed"}
{"drug_name": "Azithromycin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Azithromycin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 2)", "text": "The following clinically significant adverse reactions are described elsewhere in labeling: 5.1 [see Warnings and Precautions ( )] Hypersensitivity 5.2 [see Warnings and Precautions ( )] Hepatotoxicity 5.3 [see Warnings and Precautions ( )] Infantile Hypertrophic Pyloric Stenosis (IHPS) 5.4 [see Warnings and Precautions ( )] QT Prolongation 5.5 [see Warnings and Precautions ( )] Cardiovascular Death Clostridioides difficile- 5.6 [see Warnings and Precautions ( )] Associated Diarrhea (CDAD) 5.7 [see Warnings and Precautions ( )] Exacerbation of Myasthenia Gravis", "source": "DailyMed"}
{"drug_name": "Azithromycin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "Adverse reactions experienced at higher than recommended doses were similar to those seen at normal doses particularly nausea, diarrhea, and vomiting. In the event of overdosage, general symptomatic and supportive measures are indicated as required.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 2)", "text": "5.1 [see Warnings and Precautions ( )] Fluoroquinolones, including ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together including: 5.2 [see Warnings and Precautions ( )] Tendinitis and tendon rupture 5.3 [see Warnings and Precautions ( )] Peripheral neuropathy 5.4 [see Warnings and Precautions ( )] Central nervous system effects 5.1 [see Warnings and Precautions ( )] 5.5 [see Warnings and Precautions ( )] Discontinue ciprofloxacin immediately and avoid the use of fluoroquinolones, including ciprofloxacin, in patients who experience any of these serious adverse reactions .", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 3)", "text": "5.1 [see Warnings and Precautions ( )] Fluoroquinolones, including ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together including: 5.2 [see Warnings and Precautions ( )] Tendinitis and tendon rupture 5.3 [see Warnings and Precautions ( )] Peripheral neuropathy 5.4 [see Warnings and Precautions ( )] Central nervous system effects 5.1 [see Warnings and Precautions ( )] 5.5 [see Warnings and Precautions ( )] Discontinue ciprofloxacin immediately and avoid the use of fluoroquinolones, including ciprofloxacin, in patients who experience any of these serious adverse reactions . Fluoroquinolones, including ciprofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 4)", "text": "5.1 [see Warnings and Precautions ( )] Fluoroquinolones, including ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together including: 5.2 [see Warnings and Precautions ( )] Tendinitis and tendon rupture 5.3 [see Warnings and Precautions ( )] Peripheral neuropathy 5.4 [see Warnings and Precautions ( )] Central nervous system effects 5.1 [see Warnings and Precautions ( )] 5.5 [see Warnings and Precautions ( )] Discontinue ciprofloxacin immediately and avoid the use of fluoroquinolones, including ciprofloxacin, in patients who experience any of these serious adverse reactions . Fluoroquinolones, including ciprofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid ciprofloxacin in patients with known history of myasthenia gravis .", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 5)", "text": "5.1 [see Warnings and Precautions ( )] Fluoroquinolones, including ciprofloxacin, have been associated with disabling and potentially irreversible serious adverse reactions that have occurred together including: 5.2 [see Warnings and Precautions ( )] Tendinitis and tendon rupture 5.3 [see Warnings and Precautions ( )] Peripheral neuropathy 5.4 [see Warnings and Precautions ( )] Central nervous system effects 5.1 [see Warnings and Precautions ( )] 5.5 [see Warnings and Precautions ( )] Discontinue ciprofloxacin immediately and avoid the use of fluoroquinolones, including ciprofloxacin, in patients who experience any of these serious adverse reactions . Fluoroquinolones, including ciprofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis. Avoid ciprofloxacin in patients with known history of myasthenia gravis . 5.1 5.16 [see Warnings and Precautions ( – )] Because fluoroquinolones, including ciprofloxacin, have been associated with serious adverse reactions , reserve ciprofloxacin for use in patients who have no alternative treatment options for the following indications: 1.10 [see Indications and Usage ( )] Acute exacerbation of chronic bronchitis 1.11 [see Indications and Usage ( )] Acute uncomplicated cystitis 1.12 [see Indications and Usage ( )] Acute sinusitis", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 1)", "text": "Ciprofloxacin tablets should be administered orally as described in the appropriate Dosage Guidelines tables.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 1)", "text": "Ciprofloxacin Tablets, USP 250 mg, white, round shaped tablets, plain on one side, and “Y101” with no breakline on the other side. Ciprofloxacin Tablets, USP 500 mg, white, oval shaped tablets, plain on one side, and “Y102” with no breakline on the other side.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 2)", "text": "The following serious and otherwise important adverse drug reactions are discussed in greater detail in other sections of labeling: 5.1 [see Warnings and Precautions ( )] Disabling and Potentially Irreversible Serious Adverse Reactions 5.2 [see Warnings and Precautions ( )] Tendinitis and Tendon Rupture 5.3 [see Warnings and Precautions ( )] Peripheral Neuropathy 5.4 [see Warnings and Precautions ( )] 5.5 [see Warnings and Precautions ( )] Central Nervous System Effects Exacerbation of Myasthenia Gravis 5.6 [see Warnings and Precautions ( )] Other Serious and Sometimes Fatal Adverse Reactions 5.7 [see Warnings and Precautions ( )] Hypersensitivity Reactions 5.8 [see Warnings and Precautions ( )] Hepatotoxicity 5.9 [see Warnings and Precautions ( )] Risk of Aortic Aneurysm and Dissection 5.10 [see Warnings and Precautions ( )] Serious Adverse Reactions with Concomitant Theophylline Clostridioides difficile 5.11 [see Warnings and Precautions ( )] -Associated Diarrhea 5.12 [see Warnings and Precautions ( )] Prolongation of the QT Interval 5.13 [see Warnings and Precautions ( )] Musculoskeletal Disorders in Pediatric Patients 5.14 [see Warnings and Precautions ( )] Photosensitivity/Phototoxicity 5.15 [see Warnings and Precautions ( )] Development of Drug Resistant Bacteria", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 1)", "text": "Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Co-administration of ciprofloxacin with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 2)", "text": "Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Co-administration of ciprofloxacin with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug. Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated 4.2 [see Contraindications ( )].", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 3)", "text": "Ciprofloxacin is an inhibitor of human cytochrome P450 1A2 (CYP1A2) mediated metabolism. Co-administration of ciprofloxacin with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug. Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated 4.2 [see Contraindications ( )]. Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine Theophylline Avoid Use (Plasma Exposure Likely to be Increased and Prolonged) 5.10 [see Warnings and Precautions ( )].", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 4)", "text": "Co-administration of ciprofloxacin with other drugs primarily metabolized by CYP1A2 results in increased plasma concentrations of these drugs and could lead to clinically significant adverse events of the co-administered drug. Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated 4.2 [see Contraindications ( )]. Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine Theophylline Avoid Use (Plasma Exposure Likely to be Increased and Prolonged) 5.10 [see Warnings and Precautions ( )]. Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 5)", "text": "Table 8: Drugs That are Affected by and Affecting Ciprofloxacin Drugs That are Affected by Ciprofloxacin Drug(s) Recommendation Comments Tizanidine Contraindicated 4.2 [see Contraindications ( )]. Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine Theophylline Avoid Use (Plasma Exposure Likely to be Increased and Prolonged) 5.10 [see Warnings and Precautions ( )]. Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate Drugs Known to Prolong QT Interval Avoid Use 5.12 8.5 [see Warnings and Precautions ( ) and Use in Specific Populations ( )].", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 6)", "text": "Concomitant administration of tizanidine and ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine Theophylline Avoid Use (Plasma Exposure Likely to be Increased and Prolonged) 5.10 [see Warnings and Precautions ( )]. Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate Drugs Known to Prolong QT Interval Avoid Use 5.12 8.5 [see Warnings and Precautions ( ) and Use in Specific Populations ( )]. Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) Oral antidiabetic drugs Use with caution Glucose-lowering effect potentiated 6.1 [see Adverse Reactions ( )].", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 7)", "text": "Concurrent administration of ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate Drugs Known to Prolong QT Interval Avoid Use 5.12 8.5 [see Warnings and Precautions ( ) and Use in Specific Populations ( )]. Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) Oral antidiabetic drugs Use with caution Glucose-lowering effect potentiated 6.1 [see Adverse Reactions ( )]. Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 8)", "text": "If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate Drugs Known to Prolong QT Interval Avoid Use 5.12 8.5 [see Warnings and Precautions ( ) and Use in Specific Populations ( )]. Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) Oral antidiabetic drugs Use with caution Glucose-lowering effect potentiated 6.1 [see Adverse Reactions ( )]. Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. Fatalities have been reported.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 9)", "text": "Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) Oral antidiabetic drugs Use with caution Glucose-lowering effect potentiated 6.1 [see Adverse Reactions ( )]. Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. Fatalities have been reported. Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs Phenytoin Use with caution Altered serum levels of phenytoin (increased and decreased) To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon ciprofloxacin discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of ciprofloxacin with phenytoin.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 10)", "text": "Hypoglycemia sometimes severe has been reported when ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. Fatalities have been reported. Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs Phenytoin Use with caution Altered serum levels of phenytoin (increased and decreased) To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon ciprofloxacin discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of ciprofloxacin with phenytoin. Cyclosporine Use with caution (transient elevations in serum creatinine) Monitor renal function (in particular serum creatinine) when ciprofloxacin is co-administered with cyclosporine.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 11)", "text": "Fatalities have been reported. Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs Phenytoin Use with caution Altered serum levels of phenytoin (increased and decreased) To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon ciprofloxacin discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of ciprofloxacin with phenytoin. Cyclosporine Use with caution (transient elevations in serum creatinine) Monitor renal function (in particular serum creatinine) when ciprofloxacin is co-administered with cyclosporine. Anti-coagulant drugs Use with caution (Increase in anticoagulant effect) The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalized ratio) is difficult to assess.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 12)", "text": "Monitor blood glucose when ciprofloxacin is co-administered with oral antidiabetic drugs Phenytoin Use with caution Altered serum levels of phenytoin (increased and decreased) To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon ciprofloxacin discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of ciprofloxacin with phenytoin. Cyclosporine Use with caution (transient elevations in serum creatinine) Monitor renal function (in particular serum creatinine) when ciprofloxacin is co-administered with cyclosporine. Anti-coagulant drugs Use with caution (Increase in anticoagulant effect) The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalized ratio) is difficult to assess. Monitor prothrombin time and INR frequently during and shortly after co- administration of ciprofloxacin with an oral anti-coagulant (for example, warfarin).", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 13)", "text": "Cyclosporine Use with caution (transient elevations in serum creatinine) Monitor renal function (in particular serum creatinine) when ciprofloxacin is co-administered with cyclosporine. Anti-coagulant drugs Use with caution (Increase in anticoagulant effect) The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalized ratio) is difficult to assess. Monitor prothrombin time and INR frequently during and shortly after co- administration of ciprofloxacin with an oral anti-coagulant (for example, warfarin). Methotrexate Use with caution Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels Potential increase in the risk of methotrexate associated toxic reactions.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 14)", "text": "Anti-coagulant drugs Use with caution (Increase in anticoagulant effect) The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalized ratio) is difficult to assess. Monitor prothrombin time and INR frequently during and shortly after co- administration of ciprofloxacin with an oral anti-coagulant (for example, warfarin). Methotrexate Use with caution Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels Potential increase in the risk of methotrexate associated toxic reactions. Therefore, carefully monitor patients under methotrexate therapy when concomitant ciprofloxacin therapy is indicated.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 15)", "text": "Monitor prothrombin time and INR frequently during and shortly after co- administration of ciprofloxacin with an oral anti-coagulant (for example, warfarin). Methotrexate Use with caution Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels Potential increase in the risk of methotrexate associated toxic reactions. Therefore, carefully monitor patients under methotrexate therapy when concomitant ciprofloxacin therapy is indicated. Ropinirole Use with caution 5.16 [see Warnings and Precautions ( )].", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 16)", "text": "Methotrexate Use with caution Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels Potential increase in the risk of methotrexate associated toxic reactions. Therefore, carefully monitor patients under methotrexate therapy when concomitant ciprofloxacin therapy is indicated. Ropinirole Use with caution 5.16 [see Warnings and Precautions ( )]. Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with ciprofloxacin Clozapine Use with caution Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 17)", "text": "Therefore, carefully monitor patients under methotrexate therapy when concomitant ciprofloxacin therapy is indicated. Ropinirole Use with caution 5.16 [see Warnings and Precautions ( )]. Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with ciprofloxacin Clozapine Use with caution Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised. NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 18)", "text": "Ropinirole Use with caution 5.16 [see Warnings and Precautions ( )]. Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with ciprofloxacin Clozapine Use with caution Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised. NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. Sildenafil Use with caution Two-fold increase in exposure 12.3 [see Clinical Pharmacology ( )].", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 19)", "text": "Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after co-administration with ciprofloxacin Clozapine Use with caution Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised. NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. Sildenafil Use with caution Two-fold increase in exposure 12.3 [see Clinical Pharmacology ( )]. Monitor for sildenafil toxicity Duloxetine Avoid Use Five-fold increase in duloxetine exposure If unavoidable, monitor for duloxetine toxicity.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 20)", "text": "NSAIDs Use with caution Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing. Sildenafil Use with caution Two-fold increase in exposure 12.3 [see Clinical Pharmacology ( )]. Monitor for sildenafil toxicity Duloxetine Avoid Use Five-fold increase in duloxetine exposure If unavoidable, monitor for duloxetine toxicity. Caffeine/Xanthine Derivatives Use with caution Reduced clearance resulting in elevated levels and prolongation of serum half-life Ciprofloxacin inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products).", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 21)", "text": "Sildenafil Use with caution Two-fold increase in exposure 12.3 [see Clinical Pharmacology ( )]. Monitor for sildenafil toxicity Duloxetine Avoid Use Five-fold increase in duloxetine exposure If unavoidable, monitor for duloxetine toxicity. Caffeine/Xanthine Derivatives Use with caution Reduced clearance resulting in elevated levels and prolongation of serum half-life Ciprofloxacin inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). Monitor for xanthine toxicity and adjust dose as necessary.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 22)", "text": "Monitor for sildenafil toxicity Duloxetine Avoid Use Five-fold increase in duloxetine exposure If unavoidable, monitor for duloxetine toxicity. Caffeine/Xanthine Derivatives Use with caution Reduced clearance resulting in elevated levels and prolongation of serum half-life Ciprofloxacin inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). Monitor for xanthine toxicity and adjust dose as necessary. Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 23)", "text": "Caffeine/Xanthine Derivatives Use with caution Reduced clearance resulting in elevated levels and prolongation of serum half-life Ciprofloxacin inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). Monitor for xanthine toxicity and adjust dose as necessary. Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended. Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations ® (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) 2.4 [see Dosage and Administration ( )].", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 24)", "text": "Monitor for xanthine toxicity and adjust dose as necessary. Zolpidem Avoid Use Co-administration with ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended. Drug(s) Affecting Pharmacokinetics of Ciprofloxacin Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations ® (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; Videx (didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products) 2.4 [see Dosage and Administration ( )]. Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration Decrease ciprofloxacin absorption, resulting in lower serum and urine levels Probenecid Use with caution (interferes with renal tubular secretion of ciprofloxacin and increases ciprofloxacin serum levels) Potentiation of ciprofloxacin toxicity may occur.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "In the event of acute overdosage, reversible renal toxicity has been reported in some cases. Empty the stomach by inducing vomiting or by gastric lavage.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 2)", "text": "In the event of acute overdosage, reversible renal toxicity has been reported in some cases. Empty the stomach by inducing vomiting or by gastric lavage. Observe the patient carefully and give supportive treatment, including monitoring of renal function, urinary pH and acidify, if required, to prevent crystalluria and administration of magnesium, aluminum, or calcium containing antacids which can reduce the absorption of ciprofloxacin.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 3)", "text": "In the event of acute overdosage, reversible renal toxicity has been reported in some cases. Empty the stomach by inducing vomiting or by gastric lavage. Observe the patient carefully and give supportive treatment, including monitoring of renal function, urinary pH and acidify, if required, to prevent crystalluria and administration of magnesium, aluminum, or calcium containing antacids which can reduce the absorption of ciprofloxacin. Adequate hydration must be maintained.", "source": "DailyMed"}
{"drug_name": "Ciprofloxacin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 4)", "text": "Empty the stomach by inducing vomiting or by gastric lavage. Observe the patient carefully and give supportive treatment, including monitoring of renal function, urinary pH and acidify, if required, to prevent crystalluria and administration of magnesium, aluminum, or calcium containing antacids which can reduce the absorption of ciprofloxacin. Adequate hydration must be maintained. Only a small amount of ciprofloxacin (less than 10%) is removed from the body after hemodialysis or peritoneal dialysis.", "source": "DailyMed"}
{"drug_name": "Metformin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "Warnings and Precautions (5.1) see Overdose of metformin HCl has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [].", "source": "DailyMed"}
{"drug_name": "Metformin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 2)", "text": "Warnings and Precautions (5.1) see Overdose of metformin HCl has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases []. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions.", "source": "DailyMed"}
{"drug_name": "Metformin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 3)", "text": "Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases []. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 1)", "text": "Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 2)", "text": "Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 3)", "text": "Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 4)", "text": "Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 5)", "text": "In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 1)", "text": "2.1 Hyperlipidemia and Mixed Dyslipidemia The recommended starting dose of atorvastatin calcium tablets are 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin calcium tablets are 10 to 80 mg once daily.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 2)", "text": "2.1 Hyperlipidemia and Mixed Dyslipidemia The recommended starting dose of atorvastatin calcium tablets are 10 or 20 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin calcium tablets are 10 to 80 mg once daily. Atorvastatin calcium tablets can be administered as a single dose at any time of the day, with or without food.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 3)", "text": "Patients who require a large reduction in LDL-C (more than 45%) may be started at 40 mg once daily. The dosage range of atorvastatin calcium tablets are 10 to 80 mg once daily. Atorvastatin calcium tablets can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin calcium tablets should be individualized according to patient characteristics such as goal of therapy and response.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 4)", "text": "The dosage range of atorvastatin calcium tablets are 10 to 80 mg once daily. Atorvastatin calcium tablets can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin calcium tablets should be individualized according to patient characteristics such as goal of therapy and response. After initiation and/or upon titration of atorvastatin calcium tablets, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 5)", "text": "Atorvastatin calcium tablets can be administered as a single dose at any time of the day, with or without food. The starting dose and maintenance doses of atorvastatin calcium tablets should be individualized according to patient characteristics such as goal of therapy and response. After initiation and/or upon titration of atorvastatin calcium tablets, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly. 2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 Years to 17 Years of Age) The recommended starting dose of atorvastatin calcium tablets is 10 mg/day; the usual dose range is 20 mg orally once daily [see Clinical Studies (14.6)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 6)", "text": "The starting dose and maintenance doses of atorvastatin calcium tablets should be individualized according to patient characteristics such as goal of therapy and response. After initiation and/or upon titration of atorvastatin calcium tablets, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly. 2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 Years to 17 Years of Age) The recommended starting dose of atorvastatin calcium tablets is 10 mg/day; the usual dose range is 20 mg orally once daily [see Clinical Studies (14.6)]. Doses should be individualized according to the recommended goal of therapy [see Indications and Usage (1.2) and Clinical Pharmacology (12)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 7)", "text": "After initiation and/or upon titration of atorvastatin calcium tablets, lipid levels should be analyzed within 2 to 4 weeks and dosage adjusted accordingly. 2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 Years to 17 Years of Age) The recommended starting dose of atorvastatin calcium tablets is 10 mg/day; the usual dose range is 20 mg orally once daily [see Clinical Studies (14.6)]. Doses should be individualized according to the recommended goal of therapy [see Indications and Usage (1.2) and Clinical Pharmacology (12)]. Adjustments should be made at intervals of 4 weeks or more.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 8)", "text": "2.2 Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10 Years to 17 Years of Age) The recommended starting dose of atorvastatin calcium tablets is 10 mg/day; the usual dose range is 20 mg orally once daily [see Clinical Studies (14.6)]. Doses should be individualized according to the recommended goal of therapy [see Indications and Usage (1.2) and Clinical Pharmacology (12)]. Adjustments should be made at intervals of 4 weeks or more. 2.3 Homozygous Familial Hypercholesterolemia The dosage of atorvastatin calcium tablets in patients with HoFH is 10 to 80 mg daily.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 9)", "text": "Doses should be individualized according to the recommended goal of therapy [see Indications and Usage (1.2) and Clinical Pharmacology (12)]. Adjustments should be made at intervals of 4 weeks or more. 2.3 Homozygous Familial Hypercholesterolemia The dosage of atorvastatin calcium tablets in patients with HoFH is 10 to 80 mg daily. Atorvastatin calcium tablets should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 10)", "text": "Adjustments should be made at intervals of 4 weeks or more. 2.3 Homozygous Familial Hypercholesterolemia The dosage of atorvastatin calcium tablets in patients with HoFH is 10 to 80 mg daily. Atorvastatin calcium tablets should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable. 2.4 Concomitant Lipid-Lowering Therapy Atorvastatin calcium tablets may be used with bile acid resins.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 11)", "text": "2.3 Homozygous Familial Hypercholesterolemia The dosage of atorvastatin calcium tablets in patients with HoFH is 10 to 80 mg daily. Atorvastatin calcium tablets should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable. 2.4 Concomitant Lipid-Lowering Therapy Atorvastatin calcium tablets may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see Warnings and Precautions (5.1) and Drug Interactions (7)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 12)", "text": "Atorvastatin calcium tablets should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable. 2.4 Concomitant Lipid-Lowering Therapy Atorvastatin calcium tablets may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see Warnings and Precautions (5.1) and Drug Interactions (7)]. 2.5 Dosage in Patients with Renal Impairment Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 13)", "text": "2.4 Concomitant Lipid-Lowering Therapy Atorvastatin calcium tablets may be used with bile acid resins. The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see Warnings and Precautions (5.1) and Drug Interactions (7)]. 2.5 Dosage in Patients with Renal Impairment Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. 2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), therapy with atorvastatin should be avoided.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 14)", "text": "The combination of HMG-CoA reductase inhibitors (statins) and fibrates should generally be used with caution [see Warnings and Precautions (5.1) and Drug Interactions (7)]. 2.5 Dosage in Patients with Renal Impairment Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. 2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), therapy with atorvastatin should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary employed.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 15)", "text": "2.5 Dosage in Patients with Renal Impairment Renal disease does not affect the plasma concentrations nor LDL-C reduction of atorvastatin; thus, dosage adjustment in patients with renal dysfunction is not necessary [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. 2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), therapy with atorvastatin should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary employed. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with atorvastatin should be limited to 20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin is employed.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 16)", "text": "2.6 Dosage in Patients Taking Cyclosporine, Clarithromycin, Itraconazole, or Certain Protease Inhibitors In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), therapy with atorvastatin should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary employed. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with atorvastatin should be limited to 20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin is employed. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, therapy with atorvastatin should be limited to 40 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of atorvastatin is employed [see Warnings and Precautions (5.1) and Drug Interactions (7)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 1)", "text": "White to off-white, oval, biconvex, film-coated tablets containing 10, 20, 40, and 80 mg atorvastatin calcium.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 1)", "text": "Active Liver Disease, Which May Include Unexplained Persistent Elevations in Hepatic Transaminase Levels Hypersensitivity to Any Component of This Medication Pregnancy [see Use in Specific Populations (8.1)]. Lactation [see Use in Specific Populations (8.2)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 1)", "text": "5.1 Skeletal Muscle Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with atorvastatin and with other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 2)", "text": "5.1 Skeletal Muscle Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with atorvastatin and with other drugs in this class. A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects. Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values &gt;10 times ULN.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 3)", "text": "A history of renal impairment may be a risk factor for the development of rhabdomyolysis. Such patients merit closer monitoring for skeletal muscle effects. Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values &gt;10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 4)", "text": "Such patients merit closer monitoring for skeletal muscle effects. Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values &gt;10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis. There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 5)", "text": "Atorvastatin, like other statins, occasionally causes myopathy, defined as muscle aches or muscle weakness in conjunction with increases in creatine phosphokinase (CPK) values &gt;10 times ULN. The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis. There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 6)", "text": "The concomitant use of higher doses of atorvastatin with certain drugs such as cyclosporine and strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, and HIV protease inhibitors) increases the risk of myopathy/rhabdomyolysis. There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 7)", "text": "There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use. IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 8)", "text": "IMNM is characterized by: proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment; muscle biopsy showing necrotizing myopathy without significant inflammation; improvement with immunosuppressive agents. Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing atorvastatin. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 9)", "text": "Myopathy should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing atorvastatin. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 10)", "text": "Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever or if muscle signs and symptoms persist after discontinuing atorvastatin. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with atorvastatin and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 11)", "text": "Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with atorvastatin and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs [SEE DRUG INTERACTIONS (7)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 12)", "text": "The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, erythromycin, clarithromycin, the hepatitis C protease inhibitor telaprevir, combinations of HIV protease inhibitors, including saquinavir plus ritonavir, lopinavir plus ritonavir, tipranavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, and fosamprenavir plus ritonavir, niacin, or azole antifungals. Physicians considering combined therapy with atorvastatin and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs [SEE DRUG INTERACTIONS (7)]. Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 13)", "text": "Physicians considering combined therapy with atorvastatin and fibric acid derivatives, erythromycin, clarithromycin, a combination of saquinavir plus ritonavir, lopinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, azole antifungals, or lipid-modifying doses of niacin should carefully weigh the potential benefits and risks and should carefully monitor patients for any signs or symptoms of muscle pain, tenderness, or weakness, particularly during the initial months of therapy and during any periods of upward dosage titration of either drug. Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs [SEE DRUG INTERACTIONS (7)]. Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy. Prescribing recommendations for interacting agents are summarized in Table 2 [see DOSAGE AND ADMINISTRATION (2.6), DRUG INTERACTIONS (7), AND CLINICAL PHARMACOLOGY (12.3)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 14)", "text": "Lower starting and maintenance doses of atorvastatin should be considered when taken concomitantly with the aforementioned drugs [SEE DRUG INTERACTIONS (7)]. Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy. Prescribing recommendations for interacting agents are summarized in Table 2 [see DOSAGE AND ADMINISTRATION (2.6), DRUG INTERACTIONS (7), AND CLINICAL PHARMACOLOGY (12.3)]. Table 2.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 15)", "text": "Periodic creatine phosphokinase (CPK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent the occurrence of severe myopathy. Prescribing recommendations for interacting agents are summarized in Table 2 [see DOSAGE AND ADMINISTRATION (2.6), DRUG INTERACTIONS (7), AND CLINICAL PHARMACOLOGY (12.3)]. Table 2. Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis Interacting Agents Prescribing Recommendations * Use with caution and with the lowest dose necessary (12.3) Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir) Avoid atorvastatin HIV protease inhibitor (lopinavir plus ritonavir) Use with caution and lowest dose necessary Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir*, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) Do not exceed 20 mg atorvastatin daily HIV protease inhibitor (nelfinavir) Hepatitis C protease inhibitor (boceprevir) Do not exceed 40 mg atorvastatin daily Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see DRUG INTERACTIONS (7.11)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 16)", "text": "Prescribing recommendations for interacting agents are summarized in Table 2 [see DOSAGE AND ADMINISTRATION (2.6), DRUG INTERACTIONS (7), AND CLINICAL PHARMACOLOGY (12.3)]. Table 2. Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis Interacting Agents Prescribing Recommendations * Use with caution and with the lowest dose necessary (12.3) Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir) Avoid atorvastatin HIV protease inhibitor (lopinavir plus ritonavir) Use with caution and lowest dose necessary Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir*, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) Do not exceed 20 mg atorvastatin daily HIV protease inhibitor (nelfinavir) Hepatitis C protease inhibitor (boceprevir) Do not exceed 40 mg atorvastatin daily Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see DRUG INTERACTIONS (7.11)]. Atorvastatin therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 17)", "text": "Table 2. Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis Interacting Agents Prescribing Recommendations * Use with caution and with the lowest dose necessary (12.3) Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir) Avoid atorvastatin HIV protease inhibitor (lopinavir plus ritonavir) Use with caution and lowest dose necessary Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir*, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) Do not exceed 20 mg atorvastatin daily HIV protease inhibitor (nelfinavir) Hepatitis C protease inhibitor (boceprevir) Do not exceed 40 mg atorvastatin daily Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see DRUG INTERACTIONS (7.11)]. Atorvastatin therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures). 5.2 Liver Dysfunction Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 18)", "text": "Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis Interacting Agents Prescribing Recommendations * Use with caution and with the lowest dose necessary (12.3) Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir) Avoid atorvastatin HIV protease inhibitor (lopinavir plus ritonavir) Use with caution and lowest dose necessary Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir*, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) Do not exceed 20 mg atorvastatin daily HIV protease inhibitor (nelfinavir) Hepatitis C protease inhibitor (boceprevir) Do not exceed 40 mg atorvastatin daily Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine [see DRUG INTERACTIONS (7.11)]. Atorvastatin therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures). 5.2 Liver Dysfunction Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (&gt;3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 19)", "text": "Atorvastatin therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures). 5.2 Liver Dysfunction Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (&gt;3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 20)", "text": "5.2 Liver Dysfunction Statins, like some other lipid-lowering therapies, have been associated with biochemical abnormalities of liver function. Persistent elevations (&gt;3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively. One patient in clinical trials developed jaundice.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 21)", "text": "Persistent elevations (&gt;3 times the upper limit of normal [ULN] occurring on 2 or more occasions) in serum transaminases occurred in 0.7% of patients who received atorvastatin in clinical trials. The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively. One patient in clinical trials developed jaundice. Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 22)", "text": "The incidence of these abnormalities was 0.2%, 0.2%, 0.6%, and 2.3% for 10, 20, 40, and 80 mg, respectively. One patient in clinical trials developed jaundice. Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 23)", "text": "One patient in clinical trials developed jaundice. Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 24)", "text": "Increases in liver function tests (LFT) in other patients were not associated with jaundice or other clinical signs or symptoms. Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of atorvastatin. It is recommended that liver enzyme tests be obtained prior to initiating therapy with atorvastatin and repeated as clinically indicated.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 25)", "text": "Upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels without sequelae. Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of atorvastatin. It is recommended that liver enzyme tests be obtained prior to initiating therapy with atorvastatin and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 26)", "text": "Eighteen of 30 patients with persistent LFT elevations continued treatment with a reduced dose of atorvastatin. It is recommended that liver enzyme tests be obtained prior to initiating therapy with atorvastatin and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with atorvastatin, promptly interrupt therapy.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 27)", "text": "It is recommended that liver enzyme tests be obtained prior to initiating therapy with atorvastatin and repeated as clinically indicated. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with atorvastatin, promptly interrupt therapy. If an alternate etiology is not found, do not restart atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 28)", "text": "There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including atorvastatin. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with atorvastatin, promptly interrupt therapy. If an alternate etiology is not found, do not restart atorvastatin. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 29)", "text": "If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with atorvastatin, promptly interrupt therapy. If an alternate etiology is not found, do not restart atorvastatin. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of atorvastatin [see CONTRAINDICATIONS (4)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 30)", "text": "If an alternate etiology is not found, do not restart atorvastatin. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of atorvastatin [see CONTRAINDICATIONS (4)]. 5.3 Endocrine Function Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 31)", "text": "Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of liver disease. Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of atorvastatin [see CONTRAINDICATIONS (4)]. 5.3 Endocrine Function Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including atorvastatin. Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 32)", "text": "Active liver disease or unexplained persistent transaminase elevations are contraindications to the use of atorvastatin [see CONTRAINDICATIONS (4)]. 5.3 Endocrine Function Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including atorvastatin. Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 33)", "text": "5.3 Endocrine Function Increases in HbA1c and fasting serum glucose levels have been reported with HMG-CoA reductase inhibitors, including atorvastatin. Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 34)", "text": "Statins interfere with cholesterol synthesis and theoretically might blunt adrenal and/or gonadal steroid production. Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 35)", "text": "Clinical studies have shown that atorvastatin does not reduce basal plasma cortisol concentration or impair adrenal reserve. The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 36)", "text": "The effects of statins on male fertility have not been studied in adequate numbers of patients. The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine. 5.4 CNS Toxicity Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 37)", "text": "The effects, if any, on the pituitary-gonadal axis in premenopausal women are unknown. Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine. 5.4 CNS Toxicity Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 38)", "text": "Caution should be exercised if a statin is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and cimetidine. 5.4 CNS Toxicity Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0 to 24 hours) based on the maximum human dose of 80 mg/day.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 39)", "text": "5.4 CNS Toxicity Brain hemorrhage was seen in a female dog treated for 3 months at 120 mg/kg/day. Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0 to 24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 40)", "text": "Brain hemorrhage and optic nerve vacuolation were seen in another female dog that was sacrificed in moribund condition after 11 weeks of escalating doses up to 280 mg/kg/day. The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0 to 24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 41)", "text": "The 120 mg/kg dose resulted in a systemic exposure approximately 16 times the human plasma area-under-the-curve (AUC, 0 to 24 hours) based on the maximum human dose of 80 mg/day. A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0 to 24) based on the maximum recommended human dose of 80 mg/day.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 42)", "text": "A single tonic convulsion was seen in each of 2 male dogs (one treated at 10 mg/kg/day and one at 120 mg/kg/day) in a 2-year study. No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0 to 24) based on the maximum recommended human dose of 80 mg/day. CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 43)", "text": "No CNS lesions have been observed in mice after chronic treatment for up to 2 years at doses up to 400 mg/kg/day or in rats at doses up to 100 mg/kg/day. These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0 to 24) based on the maximum recommended human dose of 80 mg/day. CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 44)", "text": "These doses were 6 to 11 times (mouse) and 8 to 16 times (rat) the human AUC (0 to 24) based on the maximum recommended human dose of 80 mg/day. CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose. 5.5 Use in Patients with Recent Stroke or TIA In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where atorvastatin calcium 80 mg vs.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 45)", "text": "CNS vascular lesions, characterized by perivascular hemorrhages, edema, and mononuclear cell infiltration of perivascular spaces, have been observed in dogs treated with other members of this class. A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose. 5.5 Use in Patients with Recent Stroke or TIA In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where atorvastatin calcium 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the atorvastatin calcium 80 mg group compared to placebo (55, 2.3% atorvastatin vs.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 46)", "text": "A chemically similar drug in this class produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion at a dose that produced plasma drug levels about 30 times higher than the mean drug level in humans taking the highest recommended dose. 5.5 Use in Patients with Recent Stroke or TIA In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where atorvastatin calcium 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the atorvastatin calcium 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 47)", "text": "5.5 Use in Patients with Recent Stroke or TIA In a post-hoc analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study where atorvastatin calcium 80 mg vs. placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the atorvastatin calcium 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 48)", "text": "placebo was administered in 4,731 subjects without CHD who had a stroke or TIA within the preceding 6 months, a higher incidence of hemorrhagic stroke was seen in the atorvastatin calcium 80 mg group compared to placebo (55, 2.3% atorvastatin vs. 33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 49)", "text": "33, 1.4% placebo; HR: 1.68, 95% CI: 1.09, 2.59; p=0.0168). The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "warnings", "section_title": "WARNINGS AND PRECAUTIONS SECTION (chunk 50)", "text": "The incidence of fatal hemorrhagic stroke was similar across treatment groups (17 vs. 18 for the atorvastatin and placebo groups, respectively). The incidence of nonfatal hemorrhagic stroke was significantly higher in the atorvastatin group (38, 1.6%) as compared to the placebo group (16, 0.7%). Some baseline characteristics, including hemorrhagic and lacunar stroke on study entry, were associated with a higher incidence of hemorrhagic stroke in the atorvastatin group [see ADVERSE REACTIONS (6.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 2)", "text": "The following serious adverse reactions are discussed in greater detail in other sections of the label: Rhabdomyolysis and myopathy [see WARNINGS AND PRECAUTIONS (5.1)] Liver enzyme abnormalities [see WARNINGS AND PRECAUTIONS (5.2)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 3)", "text": "The following serious adverse reactions are discussed in greater detail in other sections of the label: Rhabdomyolysis and myopathy [see WARNINGS AND PRECAUTIONS (5.1)] Liver enzyme abnormalities [see WARNINGS AND PRECAUTIONS (5.2)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the atorvastatin calcium placebo-controlled clinical trial database of 16,066 patients (8755 atorvastatin calcium vs.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 4)", "text": "The following serious adverse reactions are discussed in greater detail in other sections of the label: Rhabdomyolysis and myopathy [see WARNINGS AND PRECAUTIONS (5.1)] Liver enzyme abnormalities [see WARNINGS AND PRECAUTIONS (5.2)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the atorvastatin calcium placebo-controlled clinical trial database of 16,066 patients (8755 atorvastatin calcium vs. 7311 placebo; age range 10 to 93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on atorvastatin calcium and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 5)", "text": "The following serious adverse reactions are discussed in greater detail in other sections of the label: Rhabdomyolysis and myopathy [see WARNINGS AND PRECAUTIONS (5.1)] Liver enzyme abnormalities [see WARNINGS AND PRECAUTIONS (5.2)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In the atorvastatin calcium placebo-controlled clinical trial database of 16,066 patients (8755 atorvastatin calcium vs. 7311 placebo; age range 10 to 93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on atorvastatin calcium and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with atorvastatin calcium that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 6)", "text": "In the atorvastatin calcium placebo-controlled clinical trial database of 16,066 patients (8755 atorvastatin calcium vs. 7311 placebo; age range 10 to 93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on atorvastatin calcium and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with atorvastatin calcium that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%). The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with atorvastatin calcium in placebo controlled trials (n=8755) were: nasopharyngitis (8.3%), arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection (5.7%).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 7)", "text": "7311 placebo; age range 10 to 93 years, 39% women, 91% Caucasians, 3% Blacks, 2% Asians, 4% other) with a median treatment duration of 53 weeks, 9.7% of patients on atorvastatin calcium and 9.5% of the patients on placebo discontinued due to adverse reactions regardless of causality. The five most common adverse reactions in patients treated with atorvastatin calcium that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%). The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with atorvastatin calcium in placebo controlled trials (n=8755) were: nasopharyngitis (8.3%), arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection (5.7%). Table 3 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with atorvastatin calcium (n=8755), from seventeen placebo-controlled trials.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 8)", "text": "The five most common adverse reactions in patients treated with atorvastatin calcium that led to treatment discontinuation and occurred at a rate greater than placebo were: myalgia (0.7%), diarrhea (0.5%), nausea (0.4%), alanine aminotransferase increase (0.4%), and hepatic enzyme increase (0.4%). The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with atorvastatin calcium in placebo controlled trials (n=8755) were: nasopharyngitis (8.3%), arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection (5.7%). Table 3 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with atorvastatin calcium (n=8755), from seventeen placebo-controlled trials. Table 3.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 9)", "text": "The most commonly reported adverse reactions (incidence ≥ 2% and greater than placebo) regardless of causality, in patients treated with atorvastatin calcium in placebo controlled trials (n=8755) were: nasopharyngitis (8.3%), arthralgia (6.9%), diarrhea (6.8%), pain in extremity (6.0%), and urinary tract infection (5.7%). Table 3 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with atorvastatin calcium (n=8755), from seventeen placebo-controlled trials. Table 3. Clinical adverse reactions occurring in ≥ 2% in patients treated with any dose of atorvastatin calcium and at an incidence greater than placebo regardless of causality (% of patients).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 10)", "text": "Table 3 summarizes the frequency of clinical adverse reactions, regardless of causality, reported in ≥ 2% and at a rate greater than placebo in patients treated with atorvastatin calcium (n=8755), from seventeen placebo-controlled trials. Table 3. Clinical adverse reactions occurring in ≥ 2% in patients treated with any dose of atorvastatin calcium and at an incidence greater than placebo regardless of causality (% of patients). Adverse Any dose 10 mg 20 mg 40 mg 80 mg Placebo Reaction* N=8755 N=3908 N=188 N=604 N=4055 N=7311 * Adverse Reaction ≥ 2% in any dose greater than placebo Nasopharyngitis 8.3 12.9 5.3 7.0 4.2 8.2 Arthralgia 6.9 8.9 11.7 10.6 4.3 6.5 Diarrhea 6.8 7.3 6.4 14.1 5.2 6.3 Pain in extremity 6.0 8.5 3.7 9.3 3.1 5.9 Urinary tract infection 5.7 6.9 6.4 8.0 4.1 5.6 Dyspepsia 4.7 5.9 3.2 6.0 3.3 4.3 Nausea 4.0 3.7 3.7 7.1 3.8 3.5 Musculoskeletal pain 3.8 5.2 3.2 5.1 2.3 3.6 Muscle Spasms 3.6 4.6 4.8 5.1 2.4 3.0 Myalgia 3.5 3.6 5.9 8.4 2.7 3.1 Insomnia 3.0 2.8 1.1 5.3 2.8 2.9 Pharyngolaryngeal pain 2.3 3.9 1.6 2.8 0.7 2.1 Other adverse reactions reported in placebo-controlled studies include Body as a whole: malaise, pyrexia; Digestive system: abdominal discomfort, eructation, flatulence, hepatitis, cholestasis; Musculoskeletal system: musculoskeletal pain, muscle fatigue, neck pain, joint swelling; Metabolic and nutritional system: transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia; Nervous system:nightmare; Respiratory system: epistaxis; Skin and appendages: urticaria; Special senses: vision blurred, tinnitus; Urogenital system: white blood cells urine positive.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 11)", "text": "Table 3. Clinical adverse reactions occurring in ≥ 2% in patients treated with any dose of atorvastatin calcium and at an incidence greater than placebo regardless of causality (% of patients). Adverse Any dose 10 mg 20 mg 40 mg 80 mg Placebo Reaction* N=8755 N=3908 N=188 N=604 N=4055 N=7311 * Adverse Reaction ≥ 2% in any dose greater than placebo Nasopharyngitis 8.3 12.9 5.3 7.0 4.2 8.2 Arthralgia 6.9 8.9 11.7 10.6 4.3 6.5 Diarrhea 6.8 7.3 6.4 14.1 5.2 6.3 Pain in extremity 6.0 8.5 3.7 9.3 3.1 5.9 Urinary tract infection 5.7 6.9 6.4 8.0 4.1 5.6 Dyspepsia 4.7 5.9 3.2 6.0 3.3 4.3 Nausea 4.0 3.7 3.7 7.1 3.8 3.5 Musculoskeletal pain 3.8 5.2 3.2 5.1 2.3 3.6 Muscle Spasms 3.6 4.6 4.8 5.1 2.4 3.0 Myalgia 3.5 3.6 5.9 8.4 2.7 3.1 Insomnia 3.0 2.8 1.1 5.3 2.8 2.9 Pharyngolaryngeal pain 2.3 3.9 1.6 2.8 0.7 2.1 Other adverse reactions reported in placebo-controlled studies include Body as a whole: malaise, pyrexia; Digestive system: abdominal discomfort, eructation, flatulence, hepatitis, cholestasis; Musculoskeletal system: musculoskeletal pain, muscle fatigue, neck pain, joint swelling; Metabolic and nutritional system: transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia; Nervous system:nightmare; Respiratory system: epistaxis; Skin and appendages: urticaria; Special senses: vision blurred, tinnitus; Urogenital system: white blood cells urine positive. Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) In ASCOT [see CLINICAL STUDIES (14.1)] involving 10,305 participants (age range 40 to 80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with atorvastatin calcium 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with atorvastatin calcium was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 12)", "text": "Clinical adverse reactions occurring in ≥ 2% in patients treated with any dose of atorvastatin calcium and at an incidence greater than placebo regardless of causality (% of patients). Adverse Any dose 10 mg 20 mg 40 mg 80 mg Placebo Reaction* N=8755 N=3908 N=188 N=604 N=4055 N=7311 * Adverse Reaction ≥ 2% in any dose greater than placebo Nasopharyngitis 8.3 12.9 5.3 7.0 4.2 8.2 Arthralgia 6.9 8.9 11.7 10.6 4.3 6.5 Diarrhea 6.8 7.3 6.4 14.1 5.2 6.3 Pain in extremity 6.0 8.5 3.7 9.3 3.1 5.9 Urinary tract infection 5.7 6.9 6.4 8.0 4.1 5.6 Dyspepsia 4.7 5.9 3.2 6.0 3.3 4.3 Nausea 4.0 3.7 3.7 7.1 3.8 3.5 Musculoskeletal pain 3.8 5.2 3.2 5.1 2.3 3.6 Muscle Spasms 3.6 4.6 4.8 5.1 2.4 3.0 Myalgia 3.5 3.6 5.9 8.4 2.7 3.1 Insomnia 3.0 2.8 1.1 5.3 2.8 2.9 Pharyngolaryngeal pain 2.3 3.9 1.6 2.8 0.7 2.1 Other adverse reactions reported in placebo-controlled studies include Body as a whole: malaise, pyrexia; Digestive system: abdominal discomfort, eructation, flatulence, hepatitis, cholestasis; Musculoskeletal system: musculoskeletal pain, muscle fatigue, neck pain, joint swelling; Metabolic and nutritional system: transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia; Nervous system:nightmare; Respiratory system: epistaxis; Skin and appendages: urticaria; Special senses: vision blurred, tinnitus; Urogenital system: white blood cells urine positive. Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) In ASCOT [see CLINICAL STUDIES (14.1)] involving 10,305 participants (age range 40 to 80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with atorvastatin calcium 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with atorvastatin calcium was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up. Collaborative Atorvastatin Diabetes Study (CARDS) In CARDS [see CLINICAL STUDIES (14.1)] involving 2,838 subjects (age range 39 to 77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 diabetes treated with atorvastatin calcium 10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 13)", "text": "Adverse Any dose 10 mg 20 mg 40 mg 80 mg Placebo Reaction* N=8755 N=3908 N=188 N=604 N=4055 N=7311 * Adverse Reaction ≥ 2% in any dose greater than placebo Nasopharyngitis 8.3 12.9 5.3 7.0 4.2 8.2 Arthralgia 6.9 8.9 11.7 10.6 4.3 6.5 Diarrhea 6.8 7.3 6.4 14.1 5.2 6.3 Pain in extremity 6.0 8.5 3.7 9.3 3.1 5.9 Urinary tract infection 5.7 6.9 6.4 8.0 4.1 5.6 Dyspepsia 4.7 5.9 3.2 6.0 3.3 4.3 Nausea 4.0 3.7 3.7 7.1 3.8 3.5 Musculoskeletal pain 3.8 5.2 3.2 5.1 2.3 3.6 Muscle Spasms 3.6 4.6 4.8 5.1 2.4 3.0 Myalgia 3.5 3.6 5.9 8.4 2.7 3.1 Insomnia 3.0 2.8 1.1 5.3 2.8 2.9 Pharyngolaryngeal pain 2.3 3.9 1.6 2.8 0.7 2.1 Other adverse reactions reported in placebo-controlled studies include Body as a whole: malaise, pyrexia; Digestive system: abdominal discomfort, eructation, flatulence, hepatitis, cholestasis; Musculoskeletal system: musculoskeletal pain, muscle fatigue, neck pain, joint swelling; Metabolic and nutritional system: transaminases increase, liver function test abnormal, blood alkaline phosphatase increase, creatine phosphokinase increase, hyperglycemia; Nervous system:nightmare; Respiratory system: epistaxis; Skin and appendages: urticaria; Special senses: vision blurred, tinnitus; Urogenital system: white blood cells urine positive. Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) In ASCOT [see CLINICAL STUDIES (14.1)] involving 10,305 participants (age range 40 to 80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with atorvastatin calcium 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with atorvastatin calcium was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up. Collaborative Atorvastatin Diabetes Study (CARDS) In CARDS [see CLINICAL STUDIES (14.1)] involving 2,838 subjects (age range 39 to 77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 diabetes treated with atorvastatin calcium 10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of rhabdomyolysis were reported.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 14)", "text": "Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) In ASCOT [see CLINICAL STUDIES (14.1)] involving 10,305 participants (age range 40 to 80 years, 19% women; 94.6% Caucasians, 2.6% Africans, 1.5% South Asians, 1.3% mixed/other) treated with atorvastatin calcium 10 mg daily (n=5,168) or placebo (n=5,137), the safety and tolerability profile of the group treated with atorvastatin calcium was comparable to that of the group treated with placebo during a median of 3.3 years of follow-up. Collaborative Atorvastatin Diabetes Study (CARDS) In CARDS [see CLINICAL STUDIES (14.1)] involving 2,838 subjects (age range 39 to 77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 diabetes treated with atorvastatin calcium 10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of rhabdomyolysis were reported. Treating to New Targets Study (TNT) In TNT [see CLINICAL STUDIES (14.1)] involving 10,001 subjects (age range 29 to 78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with atorvastatin calcium 10 mg daily (n=5006) or atorvastatin calcium 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 15)", "text": "Collaborative Atorvastatin Diabetes Study (CARDS) In CARDS [see CLINICAL STUDIES (14.1)] involving 2,838 subjects (age range 39 to 77 years, 32% women; 94.3% Caucasians, 2.4% South Asians, 2.3% Afro-Caribbean, 1.0% other) with type 2 diabetes treated with atorvastatin calcium 10 mg daily (n=1,428) or placebo (n=1,410), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 3.9 years. No cases of rhabdomyolysis were reported. Treating to New Targets Study (TNT) In TNT [see CLINICAL STUDIES (14.1)] involving 10,001 subjects (age range 29 to 78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with atorvastatin calcium 10 mg daily (n=5006) or atorvastatin calcium 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations (≥3 x ULN twice within 4 to 10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 16)", "text": "No cases of rhabdomyolysis were reported. Treating to New Targets Study (TNT) In TNT [see CLINICAL STUDIES (14.1)] involving 10,001 subjects (age range 29 to 78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with atorvastatin calcium 10 mg daily (n=5006) or atorvastatin calcium 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations (≥3 x ULN twice within 4 to 10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK (≥ 10 x ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 17)", "text": "Treating to New Targets Study (TNT) In TNT [see CLINICAL STUDIES (14.1)] involving 10,001 subjects (age range 29 to 78 years, 19% women; 94.1% Caucasians, 2.9% Blacks, 1.0% Asians, 2.0% other) with clinically evident CHD treated with atorvastatin calcium 10 mg daily (n=5006) or atorvastatin calcium 80 mg daily (n=4995), there were more serious adverse reactions and discontinuations due to adverse reactions in the high-dose atorvastatin group (92, 1.8%; 497, 9.9%, respectively) as compared to the low-dose group (69, 1.4%; 404, 8.1%, respectively) during a median follow-up of 4.9 years. Persistent transaminase elevations (≥3 x ULN twice within 4 to 10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK (≥ 10 x ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%). Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL) In IDEAL [see CLINICAL STUDIES (14.1)] involving 8,888 subjects (age range 26 to 80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with atorvastatin calcium 80 mg/day (n=4439) or simvastatin 20 to 40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 18)", "text": "Persistent transaminase elevations (≥3 x ULN twice within 4 to 10 days) occurred in 62 (1.3%) individuals with atorvastatin 80 mg and in nine (0.2%) individuals with atorvastatin 10 mg. Elevations of CK (≥ 10 x ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%). Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL) In IDEAL [see CLINICAL STUDIES (14.1)] involving 8,888 subjects (age range 26 to 80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with atorvastatin calcium 80 mg/day (n=4439) or simvastatin 20 to 40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) In SPARCL involving 4731 subjects (age range 21 to 92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months treated with atorvastatin calcium 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥ 3 x ULN twice within 4 to 10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 19)", "text": "Elevations of CK (≥ 10 x ULN) were low overall, but were higher in the high-dose atorvastatin treatment group (13, 0.3%) compared to the low-dose atorvastatin group (6, 0.1%). Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL) In IDEAL [see CLINICAL STUDIES (14.1)] involving 8,888 subjects (age range 26 to 80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with atorvastatin calcium 80 mg/day (n=4439) or simvastatin 20 to 40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) In SPARCL involving 4731 subjects (age range 21 to 92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months treated with atorvastatin calcium 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥ 3 x ULN twice within 4 to 10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (&gt;10 x ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 20)", "text": "Incremental Decrease in Endpoints through Aggressive Lipid Lowering Study (IDEAL) In IDEAL [see CLINICAL STUDIES (14.1)] involving 8,888 subjects (age range 26 to 80 years, 19% women; 99.3% Caucasians, 0.4% Asians, 0.3% Blacks, 0.04% other) treated with atorvastatin calcium 80 mg/day (n=4439) or simvastatin 20 to 40 mg daily (n=4449), there was no difference in the overall frequency of adverse reactions or serious adverse reactions between the treatment groups during a median follow-up of 4.8 years. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) In SPARCL involving 4731 subjects (age range 21 to 92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months treated with atorvastatin calcium 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥ 3 x ULN twice within 4 to 10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (&gt;10 x ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). Diabetes was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [seeWARNINGS AND PRECAUTIONS (5.5)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 21)", "text": "Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) In SPARCL involving 4731 subjects (age range 21 to 92 years, 40% women; 93.3% Caucasians, 3.0% Blacks, 0.6% Asians, 3.1% other) without clinically evident CHD but with a stroke or transient ischemic attack (TIA) within the previous 6 months treated with atorvastatin calcium 80 mg (n=2365) or placebo (n=2366) for a median follow-up of 4.9 years, there was a higher incidence of persistent hepatic transaminase elevations (≥ 3 x ULN twice within 4 to 10 days) in the atorvastatin group (0.9%) compared to placebo (0.1%). Elevations of CK (&gt;10 x ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). Diabetes was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [seeWARNINGS AND PRECAUTIONS (5.5)]. In a post-hoc analysis, atorvastatin calcium 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 22)", "text": "Elevations of CK (&gt;10 x ULN) were rare, but were higher in the atorvastatin group (0.1%) compared to placebo (0.0%). Diabetes was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [seeWARNINGS AND PRECAUTIONS (5.5)]. In a post-hoc analysis, atorvastatin calcium 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of hemorrhagic stroke (55/2365, 2.3% vs.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 23)", "text": "Diabetes was reported as an adverse reaction in 144 subjects (6.1%) in the atorvastatin group and 89 subjects (3.8%) in the placebo group [seeWARNINGS AND PRECAUTIONS (5.5)]. In a post-hoc analysis, atorvastatin calcium 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of hemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 24)", "text": "In a post-hoc analysis, atorvastatin calcium 80 mg reduced the incidence of ischemic stroke (218/2365, 9.2% vs. 274/2366, 11.6%) and increased the incidence of hemorrhagic stroke (55/2365, 2.3% vs. 33/2366, 1.4%) compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17 atorvastatin calcium vs. 18 placebo).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 25)", "text": "33/2366, 1.4%) compared to placebo. The incidence of fatal hemorrhagic stroke was similar between groups (17 atorvastatin calcium vs. 18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 26)", "text": "The incidence of fatal hemorrhagic stroke was similar between groups (17 atorvastatin calcium vs. 18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke [7 (16%) atorvastatin calcium vs.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 27)", "text": "18 placebo). The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke [7 (16%) atorvastatin calcium vs. 2 (4%) placebo].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 28)", "text": "The incidence of non-fatal hemorrhagic strokes was significantly greater in the atorvastatin group (38 non-fatal hemorrhagic strokes) as compared to the placebo group (16 non-fatal hemorrhagic strokes). Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke [7 (16%) atorvastatin calcium vs. 2 (4%) placebo]. There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the atorvastatin calcium 80 mg/day group vs.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 29)", "text": "Subjects who entered the study with a hemorrhagic stroke appeared to be at increased risk for hemorrhagic stroke [7 (16%) atorvastatin calcium vs. 2 (4%) placebo]. There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the atorvastatin calcium 80 mg/day group vs. 211 (8.9%) in the placebo group.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 30)", "text": "2 (4%) placebo]. There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the atorvastatin calcium 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular death were numerically smaller in the atorvastatin calcium 80 mg group (3.3%) than in the placebo group (4.1%).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 31)", "text": "There were no significant differences between the treatment groups for all-cause mortality: 216 (9.1%) in the atorvastatin calcium 80 mg/day group vs. 211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular death were numerically smaller in the atorvastatin calcium 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced non-cardiovascular death were numerically larger in the atorvastatin calcium 80 mg group (5.0%) than in the placebo group (4.0%).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 32)", "text": "211 (8.9%) in the placebo group. The proportions of subjects who experienced cardiovascular death were numerically smaller in the atorvastatin calcium 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced non-cardiovascular death were numerically larger in the atorvastatin calcium 80 mg group (5.0%) than in the placebo group (4.0%). Adverse Reactions from Clinical Studies of Atorvastatin Calcium in Pediatric Patients In a 26-week controlled study in boys and postmenarchal girls with HeFH (ages 10 years to 17 years) (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of atorvastatin calcium 10 to 20 mg daily, as an adjunct to diet to reduce total cholesterol, LDL-C, and apo B levels, was generally similar to that of placebo [see Use in Special Populations (8.4) and Clinical Studies (14.6)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 33)", "text": "The proportions of subjects who experienced cardiovascular death were numerically smaller in the atorvastatin calcium 80 mg group (3.3%) than in the placebo group (4.1%). The proportions of subjects who experienced non-cardiovascular death were numerically larger in the atorvastatin calcium 80 mg group (5.0%) than in the placebo group (4.0%). Adverse Reactions from Clinical Studies of Atorvastatin Calcium in Pediatric Patients In a 26-week controlled study in boys and postmenarchal girls with HeFH (ages 10 years to 17 years) (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of atorvastatin calcium 10 to 20 mg daily, as an adjunct to diet to reduce total cholesterol, LDL-C, and apo B levels, was generally similar to that of placebo [see Use in Special Populations (8.4) and Clinical Studies (14.6)]. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of atorvastatin calcium.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 34)", "text": "The proportions of subjects who experienced non-cardiovascular death were numerically larger in the atorvastatin calcium 80 mg group (5.0%) than in the placebo group (4.0%). Adverse Reactions from Clinical Studies of Atorvastatin Calcium in Pediatric Patients In a 26-week controlled study in boys and postmenarchal girls with HeFH (ages 10 years to 17 years) (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of atorvastatin calcium 10 to 20 mg daily, as an adjunct to diet to reduce total cholesterol, LDL-C, and apo B levels, was generally similar to that of placebo [see Use in Special Populations (8.4) and Clinical Studies (14.6)]. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of atorvastatin calcium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 35)", "text": "Adverse Reactions from Clinical Studies of Atorvastatin Calcium in Pediatric Patients In a 26-week controlled study in boys and postmenarchal girls with HeFH (ages 10 years to 17 years) (n=140, 31% female; 92% Caucasians, 1.6% Blacks, 1.6% Asians, 4.8% other), the safety and tolerability profile of atorvastatin calcium 10 to 20 mg daily, as an adjunct to diet to reduce total cholesterol, LDL-C, and apo B levels, was generally similar to that of placebo [see Use in Special Populations (8.4) and Clinical Studies (14.6)]. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of atorvastatin calcium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions associated with atorvastatin calcium therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, myositis, fatigue, tendon rupture, fatal and non-fatal hepatic failure, dizziness, depression, peripheral neuropathy, pancreatitis and interstitial lung disease.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 36)", "text": "6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of atorvastatin calcium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions associated with atorvastatin calcium therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, myositis, fatigue, tendon rupture, fatal and non-fatal hepatic failure, dizziness, depression, peripheral neuropathy, pancreatitis and interstitial lung disease. There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see WARNINGS AND PRECAUTIONS (5.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 37)", "text": "Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions associated with atorvastatin calcium therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, myositis, fatigue, tendon rupture, fatal and non-fatal hepatic failure, dizziness, depression, peripheral neuropathy, pancreatitis and interstitial lung disease. There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see WARNINGS AND PRECAUTIONS (5.1)]. There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 38)", "text": "Adverse reactions associated with atorvastatin calcium therapy reported since market introduction, that are not listed above, regardless of causality assessment, include the following: anaphylaxis, angioneurotic edema, bullous rashes (including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis), rhabdomyolysis, myositis, fatigue, tendon rupture, fatal and non-fatal hepatic failure, dizziness, depression, peripheral neuropathy, pancreatitis and interstitial lung disease. There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see WARNINGS AND PRECAUTIONS (5.1)]. There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 39)", "text": "There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see WARNINGS AND PRECAUTIONS (5.1)]. There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 1)", "text": "The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see WARNINGS AND PRECAUTIONS (5.1) andCLINICAL PHARMACOLOGY (12.3)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 2)", "text": "The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see WARNINGS AND PRECAUTIONS (5.1) andCLINICAL PHARMACOLOGY (12.3)]. 7.1 Strong Inhibitors of CYP 3A4 Atorvastatin is metabolized by cytochrome P450 3A4.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 3)", "text": "The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see WARNINGS AND PRECAUTIONS (5.1) andCLINICAL PHARMACOLOGY (12.3)]. 7.1 Strong Inhibitors of CYP 3A4 Atorvastatin is metabolized by cytochrome P450 3A4. Concomitant administration of atorvastatin with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 4)", "text": "The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole) [see WARNINGS AND PRECAUTIONS (5.1) andCLINICAL PHARMACOLOGY (12.3)]. 7.1 Strong Inhibitors of CYP 3A4 Atorvastatin is metabolized by cytochrome P450 3A4. Concomitant administration of atorvastatin with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 5)", "text": "7.1 Strong Inhibitors of CYP 3A4 Atorvastatin is metabolized by cytochrome P450 3A4. Concomitant administration of atorvastatin with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4. Clarithromycin Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 80 mg with clarithromycin (500 mg twice daily) compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 6)", "text": "Concomitant administration of atorvastatin with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin. The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4. Clarithromycin Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 80 mg with clarithromycin (500 mg twice daily) compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)]. Therefore, in patients taking clarithromycin, caution should be used when the atorvastatin dose exceeds 20 mg [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 7)", "text": "The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4. Clarithromycin Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 80 mg with clarithromycin (500 mg twice daily) compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)]. Therefore, in patients taking clarithromycin, caution should be used when the atorvastatin dose exceeds 20 mg [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)]. Combination of Protease Inhibitors Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 8)", "text": "Clarithromycin Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 80 mg with clarithromycin (500 mg twice daily) compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)]. Therefore, in patients taking clarithromycin, caution should be used when the atorvastatin dose exceeds 20 mg [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)]. Combination of Protease Inhibitors Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)]. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of atorvastatin should be avoided.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 9)", "text": "Therefore, in patients taking clarithromycin, caution should be used when the atorvastatin dose exceeds 20 mg [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)]. Combination of Protease Inhibitors Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)]. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of atorvastatin should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary should be used.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 10)", "text": "Combination of Protease Inhibitors Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)]. Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of atorvastatin should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of atorvastatin should not exceed 20 mg and should be used with caution [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 11)", "text": "Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of atorvastatin should be avoided. In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of atorvastatin should not exceed 20 mg and should be used with caution [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)]. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, the dose of atorvastatin should not exceed 40 mg and close clinical monitoring is recommended.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 12)", "text": "In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing atorvastatin and the lowest dose necessary should be used. In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of atorvastatin should not exceed 20 mg and should be used with caution [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)]. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, the dose of atorvastatin should not exceed 40 mg and close clinical monitoring is recommended. Itraconazole Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 40 mg and itraconazole 200 mg [see CLINICAL PHARMACOLOGY (12.3)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 13)", "text": "In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of atorvastatin should not exceed 20 mg and should be used with caution [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)]. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, the dose of atorvastatin should not exceed 40 mg and close clinical monitoring is recommended. Itraconazole Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 40 mg and itraconazole 200 mg [see CLINICAL PHARMACOLOGY (12.3)]. Therefore, in patients taking itraconazole, caution should be used when the atorvastatin dose exceeds 20 mg [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 14)", "text": "In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, the dose of atorvastatin should not exceed 40 mg and close clinical monitoring is recommended. Itraconazole Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 40 mg and itraconazole 200 mg [see CLINICAL PHARMACOLOGY (12.3)]. Therefore, in patients taking itraconazole, caution should be used when the atorvastatin dose exceeds 20 mg [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)]. 7.2 Grapefruit Juice Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 15)", "text": "Itraconazole Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 40 mg and itraconazole 200 mg [see CLINICAL PHARMACOLOGY (12.3)]. Therefore, in patients taking itraconazole, caution should be used when the atorvastatin dose exceeds 20 mg [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)]. 7.2 Grapefruit Juice Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day). 7.3 Cyclosporine Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 16)", "text": "Therefore, in patients taking itraconazole, caution should be used when the atorvastatin dose exceeds 20 mg [see Dosage and Administration (2.6) and Warnings and Precautions (5.1)]. 7.2 Grapefruit Juice Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day). 7.3 Cyclosporine Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 17)", "text": "7.2 Grapefruit Juice Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (&gt;1.2 liters per day). 7.3 Cyclosporine Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 18)", "text": "7.3 Cyclosporine Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter. Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)]. The co-administration of atorvastatin with cyclosporine should be avoided [see WARNINGS AND PRECAUTIONS (5.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 19)", "text": "Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin. Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)]. The co-administration of atorvastatin with cyclosporine should be avoided [see WARNINGS AND PRECAUTIONS (5.1)]. 7.4 Gemfibrozil Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of atorvastatin with gemfibrozil should be avoided [see WARNINGS AND PRECAUTIONS (5.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 20)", "text": "Atorvastatin AUC was significantly increased with concomitant administration of atorvastatin 10 mg and cyclosporine 5.2 mg/kg/day compared to that of atorvastatin alone [see CLINICAL PHARMACOLOGY (12.3)]. The co-administration of atorvastatin with cyclosporine should be avoided [see WARNINGS AND PRECAUTIONS (5.1)]. 7.4 Gemfibrozil Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of atorvastatin with gemfibrozil should be avoided [see WARNINGS AND PRECAUTIONS (5.1)]. 7.5 Other Fibrates Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, atorvastatin should be administered with caution when used concomitantly with other fibrates [see WARNINGS AND PRECAUTIONS (5.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 21)", "text": "The co-administration of atorvastatin with cyclosporine should be avoided [see WARNINGS AND PRECAUTIONS (5.1)]. 7.4 Gemfibrozil Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of atorvastatin with gemfibrozil should be avoided [see WARNINGS AND PRECAUTIONS (5.1)]. 7.5 Other Fibrates Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, atorvastatin should be administered with caution when used concomitantly with other fibrates [see WARNINGS AND PRECAUTIONS (5.1)]. 7.6 Niacin The risk of skeletal muscle effects may be enhanced when atorvastatin is used in combination with niacin; a reduction in atorvastatin dosage should be considered in this setting [see WARNINGS AND PRECAUTIONS (5.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 22)", "text": "7.4 Gemfibrozil Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of atorvastatin with gemfibrozil should be avoided [see WARNINGS AND PRECAUTIONS (5.1)]. 7.5 Other Fibrates Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, atorvastatin should be administered with caution when used concomitantly with other fibrates [see WARNINGS AND PRECAUTIONS (5.1)]. 7.6 Niacin The risk of skeletal muscle effects may be enhanced when atorvastatin is used in combination with niacin; a reduction in atorvastatin dosage should be considered in this setting [see WARNINGS AND PRECAUTIONS (5.1)]. 7.7 Rifampin or other Inducers of Cytochrome P450 3A4 Concomitant administration of atorvastatin with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 23)", "text": "7.5 Other Fibrates Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, atorvastatin should be administered with caution when used concomitantly with other fibrates [see WARNINGS AND PRECAUTIONS (5.1)]. 7.6 Niacin The risk of skeletal muscle effects may be enhanced when atorvastatin is used in combination with niacin; a reduction in atorvastatin dosage should be considered in this setting [see WARNINGS AND PRECAUTIONS (5.1)]. 7.7 Rifampin or other Inducers of Cytochrome P450 3A4 Concomitant administration of atorvastatin with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 24)", "text": "7.6 Niacin The risk of skeletal muscle effects may be enhanced when atorvastatin is used in combination with niacin; a reduction in atorvastatin dosage should be considered in this setting [see WARNINGS AND PRECAUTIONS (5.1)]. 7.7 Rifampin or other Inducers of Cytochrome P450 3A4 Concomitant administration of atorvastatin with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. 7.8 Digoxin When multiple doses of atorvastatin and digoxin were co-administered, steady state plasma digoxin concentrations increased [see Clinical Pharmacology (12.3)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 25)", "text": "7.7 Rifampin or other Inducers of Cytochrome P450 3A4 Concomitant administration of atorvastatin with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin. Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. 7.8 Digoxin When multiple doses of atorvastatin and digoxin were co-administered, steady state plasma digoxin concentrations increased [see Clinical Pharmacology (12.3)]. Patients taking digoxin should be monitored appropriately.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 26)", "text": "Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. 7.8 Digoxin When multiple doses of atorvastatin and digoxin were co-administered, steady state plasma digoxin concentrations increased [see Clinical Pharmacology (12.3)]. Patients taking digoxin should be monitored appropriately. 7.9 Oral Contraceptives Co-administration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see CLINICAL PHARMACOLOGY (12.3)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 27)", "text": "7.8 Digoxin When multiple doses of atorvastatin and digoxin were co-administered, steady state plasma digoxin concentrations increased [see Clinical Pharmacology (12.3)]. Patients taking digoxin should be monitored appropriately. 7.9 Oral Contraceptives Co-administration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see CLINICAL PHARMACOLOGY (12.3)]. These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 28)", "text": "Patients taking digoxin should be monitored appropriately. 7.9 Oral Contraceptives Co-administration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see CLINICAL PHARMACOLOGY (12.3)]. These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin. 7.10 Warfarin Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 29)", "text": "7.9 Oral Contraceptives Co-administration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol [see CLINICAL PHARMACOLOGY (12.3)]. These increases should be considered when selecting an oral contraceptive for a woman taking atorvastatin. 7.10 Warfarin Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment. 7.11 Colchicine Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "There is no specific treatment for atorvastatin overdosage. In the event of an overdose, the patient should be treated symptomatically, and supportive measures instituted as required. Due to extensive drug binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 1)", "text": "12.1 Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 2)", "text": "12.1 Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin calcium lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin calcium also reduces LDL production and the number of LDL particles.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 3)", "text": "12.1 Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin calcium lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin calcium also reduces LDL production and the number of LDL particles. 12.2 Pharmacodynamics Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 4)", "text": "12.1 Mechanism of Action Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol. In animal models, atorvastatin calcium lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin calcium also reduces LDL production and the number of LDL particles. 12.2 Pharmacodynamics Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 5)", "text": "In animal models, atorvastatin calcium lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; atorvastatin calcium also reduces LDL production and the number of LDL particles. 12.2 Pharmacodynamics Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 6)", "text": "12.2 Pharmacodynamics Atorvastatin, as well as some of its metabolites, are pharmacologically active in humans. The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see DOSAGE AND ADMINISTRATION (2)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 7)", "text": "The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance. Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see DOSAGE AND ADMINISTRATION (2)]. 12.3 Pharmacokinetics Absorption Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 8)", "text": "Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction. Individualization of drug dosage should be based on therapeutic response [see DOSAGE AND ADMINISTRATION (2)]. 12.3 Pharmacokinetics Absorption Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 9)", "text": "Individualization of drug dosage should be based on therapeutic response [see DOSAGE AND ADMINISTRATION (2)]. 12.3 Pharmacokinetics Absorption Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 10)", "text": "12.3 Pharmacokinetics Absorption Atorvastatin is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours. Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 11)", "text": "Extent of absorption increases in proportion to atorvastatin dose. The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether atorvastatin is given with or without food.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 12)", "text": "The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether atorvastatin is given with or without food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 13)", "text": "The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism. Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether atorvastatin is given with or without food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration [see DOSAGE AND ADMINISTRATION (2)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 14)", "text": "Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether atorvastatin is given with or without food. Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration [see DOSAGE AND ADMINISTRATION (2)]. Distribution Mean volume of distribution of atorvastatin is approximately 381 liters.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 15)", "text": "Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning. However, LDL-C reduction is the same regardless of the time of day of drug administration [see DOSAGE AND ADMINISTRATION (2)]. Distribution Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 16)", "text": "However, LDL-C reduction is the same regardless of the time of day of drug administration [see DOSAGE AND ADMINISTRATION (2)]. Distribution Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 17)", "text": "Distribution Mean volume of distribution of atorvastatin is approximately 381 liters. Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin is likely to be secreted in human milk [see CONTRAINDICATIONS (4) and USE IN SPECIFIC POPULATIONS (8.2)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 18)", "text": "Atorvastatin is ≥98% bound to plasma proteins. A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin is likely to be secreted in human milk [see CONTRAINDICATIONS (4) and USE IN SPECIFIC POPULATIONS (8.2)]. Metabolism Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 19)", "text": "A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells. Based on observations in rats, atorvastatin is likely to be secreted in human milk [see CONTRAINDICATIONS (4) and USE IN SPECIFIC POPULATIONS (8.2)]. Metabolism Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 20)", "text": "Based on observations in rats, atorvastatin is likely to be secreted in human milk [see CONTRAINDICATIONS (4) and USE IN SPECIFIC POPULATIONS (8.2)]. Metabolism Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 21)", "text": "Metabolism Atorvastatin is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products. In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see DRUG INTERACTIONS (7.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 22)", "text": "In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of atorvastatin. Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see DRUG INTERACTIONS (7.1)]. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 23)", "text": "Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites. In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see DRUG INTERACTIONS (7.1)]. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation. Excretion Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 24)", "text": "In vitro studies suggest the importance of atorvastatin metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of atorvastatin in humans following co-administration with erythromycin, a known inhibitor of this isozyme [see DRUG INTERACTIONS (7.1)]. In animals, the ortho-hydroxy metabolite undergoes further glucuronidation. Excretion Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 25)", "text": "In animals, the ortho-hydroxy metabolite undergoes further glucuronidation. Excretion Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 26)", "text": "Excretion Atorvastatin and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation. Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration. Specific Populations Geriatric Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 27)", "text": "Mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites. Less than 2% of a dose of atorvastatin is recovered in urine following oral administration. Specific Populations Geriatric Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population compared to younger adults [see USE IN SPECIFIC POPULATIONS (8.5)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 28)", "text": "Less than 2% of a dose of atorvastatin is recovered in urine following oral administration. Specific Populations Geriatric Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population compared to younger adults [see USE IN SPECIFIC POPULATIONS (8.5)]. Pediatric Apparent oral clearance of atorvastatin in pediatric subjects appeared similar to that of adults when scaled allometrically by body weight as the body weight was the only significant covariate in atorvastatin population PK model with data including pediatric HeFH patients (ages 10 years to 17 years of age, n=29) in an open-label, 8-week study.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 29)", "text": "Specific Populations Geriatric Plasma concentrations of atorvastatin are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age ≥65 years) than in young adults. Clinical data suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population compared to younger adults [see USE IN SPECIFIC POPULATIONS (8.5)]. Pediatric Apparent oral clearance of atorvastatin in pediatric subjects appeared similar to that of adults when scaled allometrically by body weight as the body weight was the only significant covariate in atorvastatin population PK model with data including pediatric HeFH patients (ages 10 years to 17 years of age, n=29) in an open-label, 8-week study. Gender Plasma concentrations of atorvastatin in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin between men and women.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 30)", "text": "Clinical data suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population compared to younger adults [see USE IN SPECIFIC POPULATIONS (8.5)]. Pediatric Apparent oral clearance of atorvastatin in pediatric subjects appeared similar to that of adults when scaled allometrically by body weight as the body weight was the only significant covariate in atorvastatin population PK model with data including pediatric HeFH patients (ages 10 years to 17 years of age, n=29) in an open-label, 8-week study. Gender Plasma concentrations of atorvastatin in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin between men and women. Renal Impairment Renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin; thus, dose adjustment in patients with renal dysfunction is not necessary [see DOSAGE AND ADMINISTRATION (2.5) AND WARNINGS AND PRECAUTIONS (5.1)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 31)", "text": "Pediatric Apparent oral clearance of atorvastatin in pediatric subjects appeared similar to that of adults when scaled allometrically by body weight as the body weight was the only significant covariate in atorvastatin population PK model with data including pediatric HeFH patients (ages 10 years to 17 years of age, n=29) in an open-label, 8-week study. Gender Plasma concentrations of atorvastatin in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin between men and women. Renal Impairment Renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin; thus, dose adjustment in patients with renal dysfunction is not necessary [see DOSAGE AND ADMINISTRATION (2.5) AND WARNINGS AND PRECAUTIONS (5.1)]. Hemodialysis While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of atorvastatin since the drug is extensively bound to plasma proteins.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 32)", "text": "Gender Plasma concentrations of atorvastatin in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with atorvastatin between men and women. Renal Impairment Renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin; thus, dose adjustment in patients with renal dysfunction is not necessary [see DOSAGE AND ADMINISTRATION (2.5) AND WARNINGS AND PRECAUTIONS (5.1)]. Hemodialysis While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of atorvastatin since the drug is extensively bound to plasma proteins. Hepatic Impairment In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are markedly increased.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 33)", "text": "Renal Impairment Renal disease has no influence on the plasma concentrations or LDL-C reduction of atorvastatin; thus, dose adjustment in patients with renal dysfunction is not necessary [see DOSAGE AND ADMINISTRATION (2.5) AND WARNINGS AND PRECAUTIONS (5.1)]. Hemodialysis While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of atorvastatin since the drug is extensively bound to plasma proteins. Hepatic Impairment In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 34)", "text": "Hemodialysis While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of atorvastatin since the drug is extensively bound to plasma proteins. Hepatic Impairment In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see CONTRAINDICATIONS (4)].", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 35)", "text": "Hepatic Impairment In patients with chronic alcoholic liver disease, plasma concentrations of atorvastatin are markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see CONTRAINDICATIONS (4)]. TABLE 4.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 36)", "text": "Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see CONTRAINDICATIONS (4)]. TABLE 4. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosing regimen Atorvastatin Dose (mg) Ratio of AUC&amp; Ratio of Cmax&amp; #Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD for 28 days 8.69 10.66 #Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days 10 mg, SD 9.36 8.58 #Telaprevir 750 mg q8h, 10 days 20 mg, SD 7.88 10.60 #, ‡Saquinavir 400 mg BID/ ritonavir 400 mg BID, 15 days 40 mg QD for 4 days 3.93 4.31 #Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days 4.54 5.38 #Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days 10 mg QD for 4 days 3.45 2.25 #Itraconazole 200 mg QD, 4 days 40 mg SD 3.32 1.20 #Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days 10 mg QD for 4 days 2.53 2.84 #Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days 2.30 4.04 #Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days 1.74 2.22 #Grapefruit Juice, 240 mL QD * 40 mg, SD 1.37 1.16 Diltiazem 240 mg QD, 28 days 40 mg, SD 1.51 1.00 Erythromycin 500 mg QID, 7 days 10 mg, SD 1.33 1.38 Amlodipine 10 mg, single dose 80 mg, SD 1.18 0.91 Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks 1.00 0.89 Colestipol 10 mg BID, 24 weeks 40 mg QD for 8 weeks NA 0.74** Maalox TC® 30 mL QID, 17 days 10 mg QD for 15 days 0.66 0.67 Efavirenz 600 mg QD, 14 days 10 mg for 3 days 0.59 1.01 #Rifampin 600 mg QD, 7 days (co-administered) † 40 mg SD 1.12 2.90 #Rifampin 600 mg QD, 5 days (doses separated) † 40 mg SD 0.20 0.60 #Gemfibrozil 600mg BID, 7 days 40mg SD 1.35 1.00 #Fenofibrate 160mg QD, 7 days 40mg SD 1.03 1.02 Boceprevir 800 mg TID, 7 days 40 mg SD 2.32 2.66 &amp; Represents ratio of treatments (co-administered drug plus atorvastatin vs.atorvastatin alone).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 37)", "text": "Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease [see CONTRAINDICATIONS (4)]. TABLE 4. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosing regimen Atorvastatin Dose (mg) Ratio of AUC&amp; Ratio of Cmax&amp; #Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD for 28 days 8.69 10.66 #Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days 10 mg, SD 9.36 8.58 #Telaprevir 750 mg q8h, 10 days 20 mg, SD 7.88 10.60 #, ‡Saquinavir 400 mg BID/ ritonavir 400 mg BID, 15 days 40 mg QD for 4 days 3.93 4.31 #Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days 4.54 5.38 #Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days 10 mg QD for 4 days 3.45 2.25 #Itraconazole 200 mg QD, 4 days 40 mg SD 3.32 1.20 #Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days 10 mg QD for 4 days 2.53 2.84 #Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days 2.30 4.04 #Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days 1.74 2.22 #Grapefruit Juice, 240 mL QD * 40 mg, SD 1.37 1.16 Diltiazem 240 mg QD, 28 days 40 mg, SD 1.51 1.00 Erythromycin 500 mg QID, 7 days 10 mg, SD 1.33 1.38 Amlodipine 10 mg, single dose 80 mg, SD 1.18 0.91 Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks 1.00 0.89 Colestipol 10 mg BID, 24 weeks 40 mg QD for 8 weeks NA 0.74** Maalox TC® 30 mL QID, 17 days 10 mg QD for 15 days 0.66 0.67 Efavirenz 600 mg QD, 14 days 10 mg for 3 days 0.59 1.01 #Rifampin 600 mg QD, 7 days (co-administered) † 40 mg SD 1.12 2.90 #Rifampin 600 mg QD, 5 days (doses separated) † 40 mg SD 0.20 0.60 #Gemfibrozil 600mg BID, 7 days 40mg SD 1.35 1.00 #Fenofibrate 160mg QD, 7 days 40mg SD 1.03 1.02 Boceprevir 800 mg TID, 7 days 40 mg SD 2.32 2.66 &amp; Represents ratio of treatments (co-administered drug plus atorvastatin vs.atorvastatin alone). # See Sections 5.1 and 7 for clinical significance.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 38)", "text": "TABLE 4. Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosing regimen Atorvastatin Dose (mg) Ratio of AUC&amp; Ratio of Cmax&amp; #Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD for 28 days 8.69 10.66 #Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days 10 mg, SD 9.36 8.58 #Telaprevir 750 mg q8h, 10 days 20 mg, SD 7.88 10.60 #, ‡Saquinavir 400 mg BID/ ritonavir 400 mg BID, 15 days 40 mg QD for 4 days 3.93 4.31 #Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days 4.54 5.38 #Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days 10 mg QD for 4 days 3.45 2.25 #Itraconazole 200 mg QD, 4 days 40 mg SD 3.32 1.20 #Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days 10 mg QD for 4 days 2.53 2.84 #Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days 2.30 4.04 #Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days 1.74 2.22 #Grapefruit Juice, 240 mL QD * 40 mg, SD 1.37 1.16 Diltiazem 240 mg QD, 28 days 40 mg, SD 1.51 1.00 Erythromycin 500 mg QID, 7 days 10 mg, SD 1.33 1.38 Amlodipine 10 mg, single dose 80 mg, SD 1.18 0.91 Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks 1.00 0.89 Colestipol 10 mg BID, 24 weeks 40 mg QD for 8 weeks NA 0.74** Maalox TC® 30 mL QID, 17 days 10 mg QD for 15 days 0.66 0.67 Efavirenz 600 mg QD, 14 days 10 mg for 3 days 0.59 1.01 #Rifampin 600 mg QD, 7 days (co-administered) † 40 mg SD 1.12 2.90 #Rifampin 600 mg QD, 5 days (doses separated) † 40 mg SD 0.20 0.60 #Gemfibrozil 600mg BID, 7 days 40mg SD 1.35 1.00 #Fenofibrate 160mg QD, 7 days 40mg SD 1.03 1.02 Boceprevir 800 mg TID, 7 days 40 mg SD 2.32 2.66 &amp; Represents ratio of treatments (co-administered drug plus atorvastatin vs.atorvastatin alone). # See Sections 5.1 and 7 for clinical significance. * Greater increases in AUC (ratio of AUC up to 2.5) and/or Cmax (ratio of Cmax up to 1.71) have been reported with excessive grapefruit consumption (≥ 750 mL to - 1.2 liters per day).", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 39)", "text": "Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosing regimen Atorvastatin Dose (mg) Ratio of AUC&amp; Ratio of Cmax&amp; #Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD for 28 days 8.69 10.66 #Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days 10 mg, SD 9.36 8.58 #Telaprevir 750 mg q8h, 10 days 20 mg, SD 7.88 10.60 #, ‡Saquinavir 400 mg BID/ ritonavir 400 mg BID, 15 days 40 mg QD for 4 days 3.93 4.31 #Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days 4.54 5.38 #Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days 10 mg QD for 4 days 3.45 2.25 #Itraconazole 200 mg QD, 4 days 40 mg SD 3.32 1.20 #Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days 10 mg QD for 4 days 2.53 2.84 #Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days 2.30 4.04 #Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days 1.74 2.22 #Grapefruit Juice, 240 mL QD * 40 mg, SD 1.37 1.16 Diltiazem 240 mg QD, 28 days 40 mg, SD 1.51 1.00 Erythromycin 500 mg QID, 7 days 10 mg, SD 1.33 1.38 Amlodipine 10 mg, single dose 80 mg, SD 1.18 0.91 Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks 1.00 0.89 Colestipol 10 mg BID, 24 weeks 40 mg QD for 8 weeks NA 0.74** Maalox TC® 30 mL QID, 17 days 10 mg QD for 15 days 0.66 0.67 Efavirenz 600 mg QD, 14 days 10 mg for 3 days 0.59 1.01 #Rifampin 600 mg QD, 7 days (co-administered) † 40 mg SD 1.12 2.90 #Rifampin 600 mg QD, 5 days (doses separated) † 40 mg SD 0.20 0.60 #Gemfibrozil 600mg BID, 7 days 40mg SD 1.35 1.00 #Fenofibrate 160mg QD, 7 days 40mg SD 1.03 1.02 Boceprevir 800 mg TID, 7 days 40 mg SD 2.32 2.66 &amp; Represents ratio of treatments (co-administered drug plus atorvastatin vs.atorvastatin alone). # See Sections 5.1 and 7 for clinical significance. * Greater increases in AUC (ratio of AUC up to 2.5) and/or Cmax (ratio of Cmax up to 1.71) have been reported with excessive grapefruit consumption (≥ 750 mL to - 1.2 liters per day). ** Ratio based on a single sample taken 8 to 16 h post dose.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 40)", "text": "# See Sections 5.1 and 7 for clinical significance. * Greater increases in AUC (ratio of AUC up to 2.5) and/or Cmax (ratio of Cmax up to 1.71) have been reported with excessive grapefruit consumption (≥ 750 mL to - 1.2 liters per day). ** Ratio based on a single sample taken 8 to 16 h post dose. † Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 41)", "text": "* Greater increases in AUC (ratio of AUC up to 2.5) and/or Cmax (ratio of Cmax up to 1.71) have been reported with excessive grapefruit consumption (≥ 750 mL to - 1.2 liters per day). ** Ratio based on a single sample taken 8 to 16 h post dose. † Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. ‡ The dose of saquinavir plus ritonavir in this study is not the clinically used dose.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 42)", "text": "** Ratio based on a single sample taken 8 to 16 h post dose. † Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. ‡ The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 43)", "text": "† Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations. ‡ The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 44)", "text": "‡ The dose of saquinavir plus ritonavir in this study is not the clinically used dose. The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used. TABLE 5.", "source": "DailyMed"}
{"drug_name": "Atorvastatin", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 45)", "text": "The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study. Therefore, caution should be applied and the lowest dose necessary should be used. TABLE 5. Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs Atorvastatin Co-administered drug and dosing regimen Drug/Dose (mg) Ratio of AUC Ratio of Cmax 80 mg QD for 15 days Antipyrine, 600 mg SD 1.03 0.89 80 mg QD for 10 days # Digoxin 0.25 mg QD, 20 days 1.15 1.20 40 mg QD for 22 days Oral contraceptive QD, 2 months - norethindrone 1 mg - ethinyl estradiol 35 mcg 1.28 1.19 1.23 1.30 10 mg, SD Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days 1.08 0.96 10 mg QD for 4 days Fosamprenavir 1400 mg BID, 14 days 0.73 0.82 10 mg QD for 4 days Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days 0.99 0.94 # See Section 7 for clinical significance.", "source": "DailyMed"}
{"drug_name": "Lisinopril", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "Following a single oral dose of 20 g/kg no lethality occurred in rats, and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be hypotension, for which the usual treatment would be intravenous infusion of normal saline solution. 12.3 [see CLINICAL PHARMACOLOGY ( )] Lisinopril can be removed by hemodialysis .", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 1)", "text": "Omeprazole delayed-release capsules USP, 10 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '4' hard gelatin capsule shells with opaque purple colored cap and opaque yellow colored body imprinted, 'OMERPAZOLE' over 10 mg on cap and 'R643' on body with black ink.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 2)", "text": "Omeprazole delayed-release capsules USP, 10 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '4' hard gelatin capsule shells with opaque purple colored cap and opaque yellow colored body imprinted, 'OMERPAZOLE' over 10 mg on cap and 'R643' on body with black ink. Omeprazole delayed-release capsules USP, 20 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '2' hard gelatin capsule shells with opaque purple colored cap and opaque grey colored body, imprinted 'OMEPRAZOLE' over 20 mg on cap and 'R644' on body with black ink.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 3)", "text": "Omeprazole delayed-release capsules USP, 10 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '4' hard gelatin capsule shells with opaque purple colored cap and opaque yellow colored body imprinted, 'OMERPAZOLE' over 10 mg on cap and 'R643' on body with black ink. Omeprazole delayed-release capsules USP, 20 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '2' hard gelatin capsule shells with opaque purple colored cap and opaque grey colored body, imprinted 'OMEPRAZOLE' over 20 mg on cap and 'R644' on body with black ink. Omeprazole delayed-release capsules USP, 40 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '1' hard gelatin capsule shells with opaque yellow colored cap and opaque purple colored body, imprinted 'OMEPRAZOLE' 40 mg on cap and 'R645' on body with black ink.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 1)", "text": "Warnings and Precautions (5.2) Adverse Reactions (6) [see , ]. Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 2)", "text": "Warnings and Precautions (5.2) Adverse Reactions (6) [see , ]. Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria Drug Interactions (7) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 3)", "text": "Warnings and Precautions (5.2) Adverse Reactions (6) [see , ]. Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria Drug Interactions (7) [see ]. Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 2)", "text": "The following serious adverse reactions are described below and elsewhere in labeling: Warnings and Precautions (5.2) [see ] Acute Tubulointerstitial Nephritis Clostridium Warnings and Precautions (5.3) [see ] difficile-Associated Diarrhea Warnings and Precautions (5.4) [see ] Bone Fracture Warnings and Precautions (5.6) [see ] Cutaneous and Systemic Lupus Erythematosus Warnings and Precautions (5.8) [see ] Cyanocobalamin (Vitamin B-12) Deficiency Warnings and Precautions (5.9) [see ] Hypomagnesemia and Mineral Metabolism Warnings and Precautions (5.13) [see ] Fundic Gland Polyps", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 1)", "text": "Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 2)", "text": "Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 3)", "text": "Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 4)", "text": "Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 5)", "text": "Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics Table 4: Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known. Clinical Pharmacology (12.3) [see ]. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 6)", "text": "The clinical importance and the mechanisms behind these interactions are not always known. Clinical Pharmacology (12.3) [see ]. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance Clinical Pharmacology (12.3) [see ]. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 7)", "text": "Clinical Pharmacology (12.3) [see ]. Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance Clinical Pharmacology (12.3) [see ]. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole. Intervention: Contraindications (4) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 8)", "text": "Decreased exposure of some antiretroviral drugs (e.g., rilpivirine, atazanavir and nelfinavir) when used concomitantly with omeprazole may reduce antiviral effect and promote the development of drug resistance Clinical Pharmacology (12.3) [see ]. Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole. Intervention: Contraindications (4) [see ]. Rilpivirine-containing products: Concomitant use with omeprazole is contraindicated Atazanavir: Avoid concomitant use with omeprazole.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 9)", "text": "Increased exposure of other antiretroviral drugs (e.g., saquinavir) when used concomitantly with omeprazole may increase toxicity There are other antiretroviral drugs which do not result in clinically relevant interactions with omeprazole. Intervention: Contraindications (4) [see ]. Rilpivirine-containing products: Concomitant use with omeprazole is contraindicated Atazanavir: Avoid concomitant use with omeprazole. See prescribing information for atazanavir for dosing information.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 10)", "text": "Intervention: Contraindications (4) [see ]. Rilpivirine-containing products: Concomitant use with omeprazole is contraindicated Atazanavir: Avoid concomitant use with omeprazole. See prescribing information for atazanavir for dosing information. Nelfinavir: Avoid concomitant use with omeprazole. See prescribing information for nelfinavir.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 11)", "text": "See prescribing information for atazanavir for dosing information. Nelfinavir: Avoid concomitant use with omeprazole. See prescribing information for nelfinavir. Saquinavir: See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities. Other antiretrovirals: See prescribing information for specific antiretroviral drugs.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 12)", "text": "See prescribing information for nelfinavir. Saquinavir: See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities. Other antiretrovirals: See prescribing information for specific antiretroviral drugs. Warfarin Clinical Impact: Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 13)", "text": "Saquinavir: See the prescribing information for saquinavir for monitoring of potential saquinavir-related toxicities. Other antiretrovirals: See prescribing information for specific antiretroviral drugs. Warfarin Clinical Impact: Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 14)", "text": "Other antiretrovirals: See prescribing information for specific antiretroviral drugs. Warfarin Clinical Impact: Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Intervention: Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 15)", "text": "Warfarin Clinical Impact: Increased INR and prothrombin time in patients receiving PPIs, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Intervention: Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range. Methotrexate Clinical Impact: Warnings and Precautions (5.12) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 16)", "text": "Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Intervention: Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range. Methotrexate Clinical Impact: Warnings and Precautions (5.12) [see ]. Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 17)", "text": "Intervention: Monitor INR and prothrombin time and adjust the dose of warfarin, if needed, to maintain target INR range. Methotrexate Clinical Impact: Warnings and Precautions (5.12) [see ]. Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted Intervention: A temporary withdrawal of omeprazole may be considered in some patients receiving high-dose methotrexate.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 18)", "text": "Methotrexate Clinical Impact: Warnings and Precautions (5.12) [see ]. Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted Intervention: A temporary withdrawal of omeprazole may be considered in some patients receiving high-dose methotrexate. CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam) Clopidogrel Clinical Impact: Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 19)", "text": "Concomitant use of omeprazole with methotrexate (primarily at high dose) may elevate and prolong serum concentrations of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to methotrexate toxicities. No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted Intervention: A temporary withdrawal of omeprazole may be considered in some patients receiving high-dose methotrexate. CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam) Clopidogrel Clinical Impact: Clinical Pharmacology (12.3) [see ]. Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 20)", "text": "No formal drug interaction studies of high-dose methotrexate with PPIs have been conducted Intervention: A temporary withdrawal of omeprazole may be considered in some patients receiving high-dose methotrexate. CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam) Clopidogrel Clinical Impact: Clinical Pharmacology (12.3) [see ]. Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel. Intervention: Warnings and Precautions (5.7) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 21)", "text": "CYP2C19 Substrates (e.g., clopidogrel, citalopram, cilostazol, phenytoin, diazepam) Clopidogrel Clinical Impact: Clinical Pharmacology (12.3) [see ]. Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel. Intervention: Warnings and Precautions (5.7) [see ]. Avoid concomitant use with omeprazole.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 22)", "text": "Concomitant use of omeprazole 80 mg results in reduced plasma concentrations of the active metabolite of clopidogrel and a reduction in platelet inhibition There are no adequate combination studies of a lower dose of omeprazole or a higher dose of clopidogrel in comparison with the approved dose of clopidogrel. Intervention: Warnings and Precautions (5.7) [see ]. Avoid concomitant use with omeprazole. Consider use of alternative anti-platelet therapy Citalopram Clinical Impact: Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 23)", "text": "Intervention: Warnings and Precautions (5.7) [see ]. Avoid concomitant use with omeprazole. Consider use of alternative anti-platelet therapy Citalopram Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of citalopram leading to an increased risk of QT prolongation Intervention: Limit the dose of citalopram to a maximum of 20 mg per day.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 24)", "text": "Avoid concomitant use with omeprazole. Consider use of alternative anti-platelet therapy Citalopram Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of citalopram leading to an increased risk of QT prolongation Intervention: Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing information for citalopram.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 25)", "text": "Consider use of alternative anti-platelet therapy Citalopram Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of citalopram leading to an increased risk of QT prolongation Intervention: Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing information for citalopram. Cilostazol Clinical Impact: Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 26)", "text": "Increased exposure of citalopram leading to an increased risk of QT prolongation Intervention: Limit the dose of citalopram to a maximum of 20 mg per day. See prescribing information for citalopram. Cilostazol Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) Intervention: Reduce the dose of cilostazol to 50 mg twice daily.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 27)", "text": "See prescribing information for citalopram. Cilostazol Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) Intervention: Reduce the dose of cilostazol to 50 mg twice daily. See prescribing information for cilostazol. Phenytoin Clinical Impact: Potential for increased exposure of phenytoin.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 28)", "text": "Increased exposure of one of the active metabolites of cilostazol (3,4-dihydro-cilostazol) Intervention: Reduce the dose of cilostazol to 50 mg twice daily. See prescribing information for cilostazol. Phenytoin Clinical Impact: Potential for increased exposure of phenytoin. Intervention: Monitor phenytoin serum concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 29)", "text": "Phenytoin Clinical Impact: Potential for increased exposure of phenytoin. Intervention: Monitor phenytoin serum concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for phenytoin. Diazepam Clinical Impact: Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 30)", "text": "Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for phenytoin. Diazepam Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of diazepam Intervention: Monitor patients for increased sedation and reduce the dose of diazepam as needed. Digoxin Clinical Impact: Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 31)", "text": "Diazepam Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of diazepam Intervention: Monitor patients for increased sedation and reduce the dose of diazepam as needed. Digoxin Clinical Impact: Clinical Pharmacology (12.3) [see ]. Potential for increased exposure of digoxin Intervention: Monitor digoxin concentrations.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 32)", "text": "Increased exposure of diazepam Intervention: Monitor patients for increased sedation and reduce the dose of diazepam as needed. Digoxin Clinical Impact: Clinical Pharmacology (12.3) [see ]. Potential for increased exposure of digoxin Intervention: Monitor digoxin concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See digoxin prescribing information.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 33)", "text": "Potential for increased exposure of digoxin Intervention: Monitor digoxin concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See digoxin prescribing information. Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 34)", "text": "Dose adjustment may be needed to maintain therapeutic drug concentrations. See digoxin prescribing information. Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 35)", "text": "See digoxin prescribing information. Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Clinical Pharmacology (12.3) [see ]. Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 36)", "text": "Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. Intervention: Clinical Pharmacology (12.3) [see ]. Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving omeprazole and MMF.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 37)", "text": "Intervention: Clinical Pharmacology (12.3) [see ]. Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving omeprazole and MMF. Use omeprazole with caution in transplant patients receiving MMF See the prescribing information for other drugs dependent on gastric pH for absorption.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 38)", "text": "Mycophenolate mofetil (MMF): Co-administration of omeprazole in healthy subjects and in transplant patients receiving MMF has been reported to reduce the exposure to the active metabolite, mycophenolic acid (MPA), possibly due to a decrease in MMF solubility at an increased gastric pH. The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving omeprazole and MMF. Use omeprazole with caution in transplant patients receiving MMF See the prescribing information for other drugs dependent on gastric pH for absorption. Combination Therapy with Clarithromycin and Amoxicillin Clinical Impact: Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 39)", "text": "The clinical relevance of reduced MPA exposure on organ rejection has not been established in transplant patients receiving omeprazole and MMF. Use omeprazole with caution in transplant patients receiving MMF See the prescribing information for other drugs dependent on gastric pH for absorption. Combination Therapy with Clarithromycin and Amoxicillin Clinical Impact: Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated. Amoxicillin also has drug interactions.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 40)", "text": "Use omeprazole with caution in transplant patients receiving MMF See the prescribing information for other drugs dependent on gastric pH for absorption. Combination Therapy with Clarithromycin and Amoxicillin Clinical Impact: Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated. Amoxicillin also has drug interactions. Intervention: Contraindications, Warnings and Precautions See in prescribing information for clarithromycin.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 41)", "text": "Combination Therapy with Clarithromycin and Amoxicillin Clinical Impact: Concomitant administration of clarithromycin with other drugs can lead to serious adverse reactions, including potentially fatal arrhythmias, and are contraindicated. Amoxicillin also has drug interactions. Intervention: Contraindications, Warnings and Precautions See in prescribing information for clarithromycin. Drug Interactions See in prescribing information for amoxicillin.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 42)", "text": "Amoxicillin also has drug interactions. Intervention: Contraindications, Warnings and Precautions See in prescribing information for clarithromycin. Drug Interactions See in prescribing information for amoxicillin. Tacrolimus Clinical Impact: Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 43)", "text": "Intervention: Contraindications, Warnings and Precautions See in prescribing information for clarithromycin. Drug Interactions See in prescribing information for amoxicillin. Tacrolimus Clinical Impact: Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19. Intervention: Monitor tacrolimus whole blood concentrations.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 44)", "text": "Drug Interactions See in prescribing information for amoxicillin. Tacrolimus Clinical Impact: Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19. Intervention: Monitor tacrolimus whole blood concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 45)", "text": "Tacrolimus Clinical Impact: Potential for increased exposure of tacrolimus, especially in transplant patients who are intermediate or poor metabolizers of CYP2C19. Intervention: Monitor tacrolimus whole blood concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 46)", "text": "Intervention: Monitor tacrolimus whole blood concentrations. Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus. Interactions with Investigations of Neuroendocrine Tumors Clinical Impact: Warnings and Precautions (5.11) Clinical Pharmacology (12.2) [see , ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 47)", "text": "Dose adjustment may be needed to maintain therapeutic drug concentrations. See prescribing information for tacrolimus. Interactions with Investigations of Neuroendocrine Tumors Clinical Impact: Warnings and Precautions (5.11) Clinical Pharmacology (12.2) [see , ]. Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 48)", "text": "See prescribing information for tacrolimus. Interactions with Investigations of Neuroendocrine Tumors Clinical Impact: Warnings and Precautions (5.11) Clinical Pharmacology (12.2) [see , ]. Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors Intervention: Temporarily stop omeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 49)", "text": "Interactions with Investigations of Neuroendocrine Tumors Clinical Impact: Warnings and Precautions (5.11) Clinical Pharmacology (12.2) [see , ]. Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors Intervention: Temporarily stop omeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 50)", "text": "Serum chromogranin A (CgA) levels increase secondary to PPI-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors Intervention: Temporarily stop omeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary. Interaction with Secretin Stimulation Test Clinical Impact: Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 51)", "text": "The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors Intervention: Temporarily stop omeprazole treatment at least 14 days before assessing CgA levels and consider repeating the test if initial CgA levels are high. If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary. Interaction with Secretin Stimulation Test Clinical Impact: Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma. Intervention: Clinical Pharmacology (12.2) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 52)", "text": "If serial tests are performed (e.g., for monitoring), the same commercial laboratory should be used for testing, as reference ranges between tests may vary. Interaction with Secretin Stimulation Test Clinical Impact: Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma. Intervention: Clinical Pharmacology (12.2) [see ]. Temporarily stop omeprazole treatment at least 14 days before assessing to allow gastrin levels to return to baseline False Positive Urine Tests for THC Clinical Impact: There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 53)", "text": "Interaction with Secretin Stimulation Test Clinical Impact: Hyper-response in gastrin secretion in response to secretin stimulation test, falsely suggesting gastrinoma. Intervention: Clinical Pharmacology (12.2) [see ]. Temporarily stop omeprazole treatment at least 14 days before assessing to allow gastrin levels to return to baseline False Positive Urine Tests for THC Clinical Impact: There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs. Intervention: An alternative confirmatory method should be considered to verify positive results.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 54)", "text": "Intervention: Clinical Pharmacology (12.2) [see ]. Temporarily stop omeprazole treatment at least 14 days before assessing to allow gastrin levels to return to baseline False Positive Urine Tests for THC Clinical Impact: There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs. Intervention: An alternative confirmatory method should be considered to verify positive results. Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram).", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 55)", "text": "Temporarily stop omeprazole treatment at least 14 days before assessing to allow gastrin levels to return to baseline False Positive Urine Tests for THC Clinical Impact: There have been reports of false positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving PPIs. Intervention: An alternative confirmatory method should be considered to verify positive results. Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). Intervention: Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with omeprazole.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 56)", "text": "Intervention: An alternative confirmatory method should be considered to verify positive results. Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). Intervention: Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with omeprazole. CYP2C19 or CYP3A4 Inducers Clinical Impact: Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 57)", "text": "Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). Intervention: Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with omeprazole. CYP2C19 or CYP3A4 Inducers Clinical Impact: Clinical Pharmacology (12.3) [see ]. Decreased exposure of omeprazole when used concomitantly with strong inducers Intervention: Warnings and Precautions (5.10) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 58)", "text": "Intervention: Monitor patients to determine if it is necessary to adjust the dosage of these other drugs when taken concomitantly with omeprazole. CYP2C19 or CYP3A4 Inducers Clinical Impact: Clinical Pharmacology (12.3) [see ]. Decreased exposure of omeprazole when used concomitantly with strong inducers Intervention: Warnings and Precautions (5.10) [see ]. St.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 59)", "text": "CYP2C19 or CYP3A4 Inducers Clinical Impact: Clinical Pharmacology (12.3) [see ]. Decreased exposure of omeprazole when used concomitantly with strong inducers Intervention: Warnings and Precautions (5.10) [see ]. St. John’s Wort, rifampin: Avoid concomitant use with omeprazole Ritonavir-containing products: see prescribing information for specific drugs.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 60)", "text": "Decreased exposure of omeprazole when used concomitantly with strong inducers Intervention: Warnings and Precautions (5.10) [see ]. St. John’s Wort, rifampin: Avoid concomitant use with omeprazole Ritonavir-containing products: see prescribing information for specific drugs. CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Clinical Pharmacology (12.3) [see ].", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 61)", "text": "St. John’s Wort, rifampin: Avoid concomitant use with omeprazole Ritonavir-containing products: see prescribing information for specific drugs. CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of omeprazole Intervention: Voriconazole: Dose adjustment of omeprazole is not normally required.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 62)", "text": "John’s Wort, rifampin: Avoid concomitant use with omeprazole Ritonavir-containing products: see prescribing information for specific drugs. CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of omeprazole Intervention: Voriconazole: Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses, dose adjustment may be considered.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "interactions", "section_title": "DRUG INTERACTIONS SECTION (chunk 63)", "text": "CYP2C19 or CYP3A4 Inhibitors Clinical Impact: Clinical Pharmacology (12.3) [see ]. Increased exposure of omeprazole Intervention: Voriconazole: Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses, dose adjustment may be considered. See prescribing information for voriconazole.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "Adverse Reactions (6) [see ]. Reports have been received of overdosage with omeprazole in humans. Doses ranged up to 2400 mg (120 times the usual recommended clinical dose).", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 2)", "text": "Adverse Reactions (6) [see ]. Reports have been received of overdosage with omeprazole in humans. Doses ranged up to 2400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 3)", "text": "Reports have been received of overdosage with omeprazole in humans. Doses ranged up to 2400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone. No specific antidote for omeprazole overdosage is known.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 4)", "text": "Doses ranged up to 2400 mg (120 times the usual recommended clinical dose). Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone. No specific antidote for omeprazole overdosage is known. Omeprazole is extensively protein bound and is, therefore, not readily dialyzable.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 5)", "text": "Manifestations were variable, but included confusion, drowsiness, blurred vision, tachycardia, nausea, vomiting, diaphoresis, flushing, headache, dry mouth, and other adverse reactions similar to those seen in normal clinical experience Symptoms were transient, and no serious clinical outcome has been reported when omeprazole was taken alone. No specific antidote for omeprazole overdosage is known. Omeprazole is extensively protein bound and is, therefore, not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive.", "source": "DailyMed"}
{"drug_name": "Omeprazole", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 6)", "text": "No specific antidote for omeprazole overdosage is known. Omeprazole is extensively protein bound and is, therefore, not readily dialyzable. In the event of overdosage, treatment should be symptomatic and supportive. If over-exposure occurs, call your Poison Control Center at 1-800-222-1222 for current information on the management of poisoning or overdosage.", "source": "DailyMed"}
{"drug_name": "Levothyroxine", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 1)", "text": "Keep out of reach of children. In case of overdose, contact physician or a Poison Control Center right away. If pregnant or breast-feeding, ask a health professional before use. Tamper seal: \"Sealed for Your Protection.\" Do not use if seal is broken or missing.", "source": "DailyMed"}
{"drug_name": "Levothyroxine", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 1)", "text": "1-10 drops under the tongue, 3 times a day or as directed by a health professional. Consult a physician for use in children under 12 years of age.", "source": "DailyMed"}
{"drug_name": "Levothyroxine", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 1)", "text": "For the temporary relief of symptoms such as backache, constipation, and vomiting.** **These statements are based upon traditional homeopathic principles. They have not been reviewed by the Food and Drug Administration.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 1)", "text": "In vitro in vivo 2 2 2 studies and pharmacologic studies have demonstrated that albuterol has a preferential effect on beta -adrenergic receptors compared with isoproterenol.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 2)", "text": "In vitro in vivo 2 2 2 studies and pharmacologic studies have demonstrated that albuterol has a preferential effect on beta -adrenergic receptors compared with isoproterenol. While it is recognized that beta -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta -receptors in the human heart existing in a concentration between 10% and 50%.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 3)", "text": "In vitro in vivo 2 2 2 studies and pharmacologic studies have demonstrated that albuterol has a preferential effect on beta -adrenergic receptors compared with isoproterenol. While it is recognized that beta -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta -receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established (see WARNINGS).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 4)", "text": "In vitro in vivo 2 2 2 studies and pharmacologic studies have demonstrated that albuterol has a preferential effect on beta -adrenergic receptors compared with isoproterenol. While it is recognized that beta -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta -receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established (see WARNINGS). The pharmacologic effects of beta-adrenergic agonist drugs, including albuterol tablets, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'- adenosine monophosphate (cyclic AMP).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 5)", "text": "While it is recognized that beta -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta -receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established (see WARNINGS). The pharmacologic effects of beta-adrenergic agonist drugs, including albuterol tablets, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'- adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 6)", "text": "The precise function of these receptors has not been established (see WARNINGS). The pharmacologic effects of beta-adrenergic agonist drugs, including albuterol tablets, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'- adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Albuterol tablets have been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "mechanism", "section_title": "CLINICAL PHARMACOLOGY SECTION (chunk 7)", "text": "The pharmacologic effects of beta-adrenergic agonist drugs, including albuterol tablets, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'- adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Albuterol tablets have been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects. O Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol- -methyl transferase.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 1)", "text": "Albuterol tablets are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 1)", "text": "Albuterol tablets are contraindicated in patients with a history of hypersensitivity to albuterol, or any of its components.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 1)", "text": "Paradoxical Bronchospasm Cardiovascular Effects Albuterol tablets can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, albuterol tablets should be discontinued immediately and alternative therapy instituted.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 2)", "text": "Paradoxical Bronchospasm Cardiovascular Effects Albuterol tablets can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, albuterol tablets should be discontinued immediately and alternative therapy instituted. Albuterol tablets, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 3)", "text": "Paradoxical Bronchospasm Cardiovascular Effects Albuterol tablets can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, albuterol tablets should be discontinued immediately and alternative therapy instituted. Albuterol tablets, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of albuterol tablets at recommended doses, if they occur, the drug may need to be discontinued.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 4)", "text": "If paradoxical bronchospasm occurs, albuterol tablets should be discontinued immediately and alternative therapy instituted. Albuterol tablets, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of albuterol tablets at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 5)", "text": "Albuterol tablets, like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of albuterol tablets at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 6)", "text": "Although such effects are uncommon after administration of albuterol tablets at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, albuterol tablets, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 7)", "text": "In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, albuterol tablets, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Deterioration of Asthma Asthma may deteriorate acutely over a period of hours, or chronically over several days or longer.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 8)", "text": "The clinical significance of these findings is unknown. Therefore, albuterol tablets, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Deterioration of Asthma Asthma may deteriorate acutely over a period of hours, or chronically over several days or longer. If the patient needs more doses of albuterol tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 9)", "text": "Therefore, albuterol tablets, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Deterioration of Asthma Asthma may deteriorate acutely over a period of hours, or chronically over several days or longer. If the patient needs more doses of albuterol tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. Use of Anti-Inflammatory Agents The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 10)", "text": "Deterioration of Asthma Asthma may deteriorate acutely over a period of hours, or chronically over several days or longer. If the patient needs more doses of albuterol tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. Use of Anti-Inflammatory Agents The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 11)", "text": "If the patient needs more doses of albuterol tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. Use of Anti-Inflammatory Agents The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids. Immediate Hypersensitivity Reactions Immediate hypersensitivity reactions may occur after administration of albuterol tablets, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm and oropharyngeal edema.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 12)", "text": "Use of Anti-Inflammatory Agents The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids. Immediate Hypersensitivity Reactions Immediate hypersensitivity reactions may occur after administration of albuterol tablets, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm and oropharyngeal edema. Albuterol tablets, like other beta-adrenergic agonists, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "WARNINGS SECTION (chunk 13)", "text": "Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids. Immediate Hypersensitivity Reactions Immediate hypersensitivity reactions may occur after administration of albuterol tablets, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm and oropharyngeal edema. Albuterol tablets, like other beta-adrenergic agonists, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes. Rarely, erythema multiforme and Stevens-Johnson syndrome have been associated with the administration of oral albuterol sulfate in children.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 1)", "text": "General Albuterol tablets, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 2)", "text": "General Albuterol tablets, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 3)", "text": "General Albuterol tablets, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator. Large doses of intravenous albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 4)", "text": "General Albuterol tablets, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator. Large doses of intravenous albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. As with other beta-agonists, albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 5)", "text": "Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator. Large doses of intravenous albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. As with other beta-agonists, albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 6)", "text": "Large doses of intravenous albuterol have been reported to aggravate preexisting diabetes mellitus and ketoacidosis. As with other beta-agonists, albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation. Information for patients The action of albuterol tablets may last up to 8 hours or longer.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 7)", "text": "As with other beta-agonists, albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation. Information for patients The action of albuterol tablets may last up to 8 hours or longer. Albuterol tablets should not be taken more frequently than recommended.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 8)", "text": "The decrease is usually transient, not requiring supplementation. Information for patients The action of albuterol tablets may last up to 8 hours or longer. Albuterol tablets should not be taken more frequently than recommended. Do not increase the dose or frequency of albuterol tablets without consulting your physician.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 9)", "text": "Information for patients The action of albuterol tablets may last up to 8 hours or longer. Albuterol tablets should not be taken more frequently than recommended. Do not increase the dose or frequency of albuterol tablets without consulting your physician. If you find that treatment with albuterol tablets becomes less effective for symptomatic relief, your symptoms get worse, and/or you need to take the product more frequently than usual, you should seek medical attention immediately.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 10)", "text": "Albuterol tablets should not be taken more frequently than recommended. Do not increase the dose or frequency of albuterol tablets without consulting your physician. If you find that treatment with albuterol tablets becomes less effective for symptomatic relief, your symptoms get worse, and/or you need to take the product more frequently than usual, you should seek medical attention immediately. While you are taking albuterol tablets, other asthma medications and inhaled drugs should be taken only as directed by your physician.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 11)", "text": "Do not increase the dose or frequency of albuterol tablets without consulting your physician. If you find that treatment with albuterol tablets becomes less effective for symptomatic relief, your symptoms get worse, and/or you need to take the product more frequently than usual, you should seek medical attention immediately. While you are taking albuterol tablets, other asthma medications and inhaled drugs should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, and tremor or nervousness.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 12)", "text": "If you find that treatment with albuterol tablets becomes less effective for symptomatic relief, your symptoms get worse, and/or you need to take the product more frequently than usual, you should seek medical attention immediately. While you are taking albuterol tablets, other asthma medications and inhaled drugs should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, and tremor or nervousness. If you are pregnant or nursing, contact your physician about use of albuterol tablets.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 13)", "text": "While you are taking albuterol tablets, other asthma medications and inhaled drugs should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, and tremor or nervousness. If you are pregnant or nursing, contact your physician about use of albuterol tablets. Effective and safe use of albuterol tablets includes an understanding of the way that it should be administered.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 14)", "text": "Common adverse effects include palpitations, chest pain, rapid heart rate, and tremor or nervousness. If you are pregnant or nursing, contact your physician about use of albuterol tablets. Effective and safe use of albuterol tablets includes an understanding of the way that it should be administered. Drug interactions The concomitant use of albuterol tablets and other oral sympathomimetic agents is not recommended since such combined use may lead to deleterious cardiovascular effects.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 15)", "text": "If you are pregnant or nursing, contact your physician about use of albuterol tablets. Effective and safe use of albuterol tablets includes an understanding of the way that it should be administered. Drug interactions The concomitant use of albuterol tablets and other oral sympathomimetic agents is not recommended since such combined use may lead to deleterious cardiovascular effects. This recommendation does not preclude the judicious use of an aerosol bronchodilator of the adrenergic stimulant type in patients receiving albuterol tablets.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 16)", "text": "Effective and safe use of albuterol tablets includes an understanding of the way that it should be administered. Drug interactions The concomitant use of albuterol tablets and other oral sympathomimetic agents is not recommended since such combined use may lead to deleterious cardiovascular effects. This recommendation does not preclude the judicious use of an aerosol bronchodilator of the adrenergic stimulant type in patients receiving albuterol tablets. Such concomitant use, however, should be individualized and not given on a routine basis.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 17)", "text": "Drug interactions The concomitant use of albuterol tablets and other oral sympathomimetic agents is not recommended since such combined use may lead to deleterious cardiovascular effects. This recommendation does not preclude the judicious use of an aerosol bronchodilator of the adrenergic stimulant type in patients receiving albuterol tablets. Such concomitant use, however, should be individualized and not given on a routine basis. If regular coadministration is required, then alternative therapy should be considered.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 18)", "text": "This recommendation does not preclude the judicious use of an aerosol bronchodilator of the adrenergic stimulant type in patients receiving albuterol tablets. Such concomitant use, however, should be individualized and not given on a routine basis. If regular coadministration is required, then alternative therapy should be considered. Monamine Oxidase Inhibitors or Tricyclic Antidepressants Albuterol tablets should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol tablets on the vascular system may be potentiated.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 19)", "text": "Such concomitant use, however, should be individualized and not given on a routine basis. If regular coadministration is required, then alternative therapy should be considered. Monamine Oxidase Inhibitors or Tricyclic Antidepressants Albuterol tablets should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol tablets on the vascular system may be potentiated. Beta-Blockers Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as albuterol tablets, but may produce severe bronchospasm in asthmatic patients.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 20)", "text": "If regular coadministration is required, then alternative therapy should be considered. Monamine Oxidase Inhibitors or Tricyclic Antidepressants Albuterol tablets should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol tablets on the vascular system may be potentiated. Beta-Blockers Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as albuterol tablets, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 21)", "text": "Monamine Oxidase Inhibitors or Tricyclic Antidepressants Albuterol tablets should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of albuterol tablets on the vascular system may be potentiated. Beta-Blockers Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as albuterol tablets, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 22)", "text": "Beta-Blockers Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as albuterol tablets, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 23)", "text": "Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. Diuretics The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 24)", "text": "However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. Diuretics The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 25)", "text": "In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. Diuretics The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics. Digoxin Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 26)", "text": "Diuretics The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics. Digoxin Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 27)", "text": "Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics. Digoxin Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 28)", "text": "Digoxin Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol. Carcinogenesis, Mutagenesis, Impairment of Fertility 2 2 In a 2-year study in Sprague-Dawley rats, albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 2, 10, and 50 mg/kg (approximately 1/2 , 3, and 15 times, respectively, the maximum recommended daily oral dose for adults on a mg/m basis, or, 2/5 , 2 and 10 times, respectively, the maximum recommended daily oral dose for children on a mg/m basis).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 29)", "text": "The clinical significance of these findings for patients with obstructive airway disease who are receiving albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol. Carcinogenesis, Mutagenesis, Impairment of Fertility 2 2 In a 2-year study in Sprague-Dawley rats, albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 2, 10, and 50 mg/kg (approximately 1/2 , 3, and 15 times, respectively, the maximum recommended daily oral dose for adults on a mg/m basis, or, 2/5 , 2 and 10 times, respectively, the maximum recommended daily oral dose for children on a mg/m basis). In another study this effect was blocked by the coadministration of propranolol, a non-selective beta-adrenergic antagonist.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 30)", "text": "Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and albuterol. Carcinogenesis, Mutagenesis, Impairment of Fertility 2 2 In a 2-year study in Sprague-Dawley rats, albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 2, 10, and 50 mg/kg (approximately 1/2 , 3, and 15 times, respectively, the maximum recommended daily oral dose for adults on a mg/m basis, or, 2/5 , 2 and 10 times, respectively, the maximum recommended daily oral dose for children on a mg/m basis). In another study this effect was blocked by the coadministration of propranolol, a non-selective beta-adrenergic antagonist. 2 2 2 2 In an 18-month study in CD-1 mice albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg, (approximately 65 times the maximum recommended daily oral dose for adults on an mg/m basis, or, approximately 50 times the maximum recommended daily oral dose for children on an mg/m basis).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 31)", "text": "Carcinogenesis, Mutagenesis, Impairment of Fertility 2 2 In a 2-year study in Sprague-Dawley rats, albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 2, 10, and 50 mg/kg (approximately 1/2 , 3, and 15 times, respectively, the maximum recommended daily oral dose for adults on a mg/m basis, or, 2/5 , 2 and 10 times, respectively, the maximum recommended daily oral dose for children on a mg/m basis). In another study this effect was blocked by the coadministration of propranolol, a non-selective beta-adrenergic antagonist. 2 2 2 2 In an 18-month study in CD-1 mice albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg, (approximately 65 times the maximum recommended daily oral dose for adults on an mg/m basis, or, approximately 50 times the maximum recommended daily oral dose for children on an mg/m basis). In a 22-month study in the Golden hamster, albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg, (approximately 8 times the maximum recommended daily oral dose for adults on a mg/m basis, or, approximately 7 times the maximum recommended daily oral dose for children on a mg/m basis).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 32)", "text": "In another study this effect was blocked by the coadministration of propranolol, a non-selective beta-adrenergic antagonist. 2 2 2 2 In an 18-month study in CD-1 mice albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg, (approximately 65 times the maximum recommended daily oral dose for adults on an mg/m basis, or, approximately 50 times the maximum recommended daily oral dose for children on an mg/m basis). In a 22-month study in the Golden hamster, albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg, (approximately 8 times the maximum recommended daily oral dose for adults on a mg/m basis, or, approximately 7 times the maximum recommended daily oral dose for children on a mg/m basis). S.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 33)", "text": "2 2 2 2 In an 18-month study in CD-1 mice albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg, (approximately 65 times the maximum recommended daily oral dose for adults on an mg/m basis, or, approximately 50 times the maximum recommended daily oral dose for children on an mg/m basis). In a 22-month study in the Golden hamster, albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg, (approximately 8 times the maximum recommended daily oral dose for adults on a mg/m basis, or, approximately 7 times the maximum recommended daily oral dose for children on a mg/m basis). S. typhimurium E.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 34)", "text": "In a 22-month study in the Golden hamster, albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg, (approximately 8 times the maximum recommended daily oral dose for adults on a mg/m basis, or, approximately 7 times the maximum recommended daily oral dose for children on a mg/m basis). S. typhimurium E. Coli S. cerevisiae S. cerevisiae S. typhimurium E.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 35)", "text": "cerevisiae S. cerevisiae S. typhimurium E. Coli 2 Albuterol sulfate was not mutagenic in the Ames test with or without metabolic activation using tester strains TA1537, TA1538, and TA98 or WP2, WP2uvrA, and WP67. No forward mutation was seen in yeast strain S9 nor any mitotic gene conversion in yeast strain JD1 with or without metabolic activation.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 36)", "text": "typhimurium E. Coli 2 Albuterol sulfate was not mutagenic in the Ames test with or without metabolic activation using tester strains TA1537, TA1538, and TA98 or WP2, WP2uvrA, and WP67. No forward mutation was seen in yeast strain S9 nor any mitotic gene conversion in yeast strain JD1 with or without metabolic activation. Fluctuation assays in TA98 and WP2, both with metabolic activation, were negative.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 37)", "text": "Coli 2 Albuterol sulfate was not mutagenic in the Ames test with or without metabolic activation using tester strains TA1537, TA1538, and TA98 or WP2, WP2uvrA, and WP67. No forward mutation was seen in yeast strain S9 nor any mitotic gene conversion in yeast strain JD1 with or without metabolic activation. Fluctuation assays in TA98 and WP2, both with metabolic activation, were negative. Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at intraperitoneal doses of up to 200 mg/kg.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 38)", "text": "No forward mutation was seen in yeast strain S9 nor any mitotic gene conversion in yeast strain JD1 with or without metabolic activation. Fluctuation assays in TA98 and WP2, both with metabolic activation, were negative. Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at intraperitoneal doses of up to 200 mg/kg. Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg (approximately 15 times the maximum recommended daily oral dose for adults on a mg/m basis).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 39)", "text": "Fluctuation assays in TA98 and WP2, both with metabolic activation, were negative. Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at intraperitoneal doses of up to 200 mg/kg. Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg (approximately 15 times the maximum recommended daily oral dose for adults on a mg/m basis). Pregnancy Teratogenic Effects 2 2 Albuterol tablets have been shown to be teratogenic in mice.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 40)", "text": "Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at intraperitoneal doses of up to 200 mg/kg. Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg (approximately 15 times the maximum recommended daily oral dose for adults on a mg/m basis). Pregnancy Teratogenic Effects 2 2 Albuterol tablets have been shown to be teratogenic in mice. A study in CD-1 mice at subcutaneous (sc) doses of 0.025, 0.25, and 2.5 mg/kg (approximately 3/1000, 3/100, and 3/10 times, respectively, the maximum recommended daily oral dose for adults on a mg/m basis), showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 41)", "text": "Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg (approximately 15 times the maximum recommended daily oral dose for adults on a mg/m basis). Pregnancy Teratogenic Effects 2 2 Albuterol tablets have been shown to be teratogenic in mice. A study in CD-1 mice at subcutaneous (sc) doses of 0.025, 0.25, and 2.5 mg/kg (approximately 3/1000, 3/100, and 3/10 times, respectively, the maximum recommended daily oral dose for adults on a mg/m basis), showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. The drug did not induce cleft palate formation at the lowest, 0.025 mg/kg.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 42)", "text": "Pregnancy Teratogenic Effects 2 2 Albuterol tablets have been shown to be teratogenic in mice. A study in CD-1 mice at subcutaneous (sc) doses of 0.025, 0.25, and 2.5 mg/kg (approximately 3/1000, 3/100, and 3/10 times, respectively, the maximum recommended daily oral dose for adults on a mg/m basis), showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. The drug did not induce cleft palate formation at the lowest, 0.025 mg/kg. Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated with 2.5 mg/kg of isoproterenol (positive control) subcutaneously (approximately 3/10 times the maximum recommended daily oral dose for adults on a mg/m basis).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 43)", "text": "A study in CD-1 mice at subcutaneous (sc) doses of 0.025, 0.25, and 2.5 mg/kg (approximately 3/1000, 3/100, and 3/10 times, respectively, the maximum recommended daily oral dose for adults on a mg/m basis), showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. The drug did not induce cleft palate formation at the lowest, 0.025 mg/kg. Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated with 2.5 mg/kg of isoproterenol (positive control) subcutaneously (approximately 3/10 times the maximum recommended daily oral dose for adults on a mg/m basis). 2 A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses when albuterol tablets were administered orally at a 50 mg/kg dose (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m basis).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 44)", "text": "The drug did not induce cleft palate formation at the lowest, 0.025 mg/kg. Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated with 2.5 mg/kg of isoproterenol (positive control) subcutaneously (approximately 3/10 times the maximum recommended daily oral dose for adults on a mg/m basis). 2 A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses when albuterol tablets were administered orally at a 50 mg/kg dose (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m basis). There are no adequate and well-controlled studies in pregnant women.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 45)", "text": "Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated with 2.5 mg/kg of isoproterenol (positive control) subcutaneously (approximately 3/10 times the maximum recommended daily oral dose for adults on a mg/m basis). 2 A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses when albuterol tablets were administered orally at a 50 mg/kg dose (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m basis). There are no adequate and well-controlled studies in pregnant women. Albuterol tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 46)", "text": "2 A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses when albuterol tablets were administered orally at a 50 mg/kg dose (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m basis). There are no adequate and well-controlled studies in pregnant women. Albuterol tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been rarely reported in the offspring of patients being treated with albuterol tablets.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 47)", "text": "There are no adequate and well-controlled studies in pregnant women. Albuterol tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been rarely reported in the offspring of patients being treated with albuterol tablets. Some of the mothers were taking multiple medications during their pregnancies.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 48)", "text": "Albuterol tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been rarely reported in the offspring of patients being treated with albuterol tablets. Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned and a relationship between albuterol tablets use and congenital anomalies has not been established.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 49)", "text": "During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been rarely reported in the offspring of patients being treated with albuterol tablets. Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned and a relationship between albuterol tablets use and congenital anomalies has not been established. Use in Labor and Delivery Tocolysis Nursing Mothers Pediatric Use 2 Because of the potential for beta-agonist interference with uterine contractility, use of albuterol tablets for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 50)", "text": "Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned and a relationship between albuterol tablets use and congenital anomalies has not been established. Use in Labor and Delivery Tocolysis Nursing Mothers Pediatric Use 2 Because of the potential for beta-agonist interference with uterine contractility, use of albuterol tablets for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk. Albuterol tablets have not been approved for the management of preterm labor.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 51)", "text": "No consistent pattern of defects can be discerned and a relationship between albuterol tablets use and congenital anomalies has not been established. Use in Labor and Delivery Tocolysis Nursing Mothers Pediatric Use 2 Because of the potential for beta-agonist interference with uterine contractility, use of albuterol tablets for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk. Albuterol tablets have not been approved for the management of preterm labor. The benefit: risk ratio when albuterol tablets are administered for tocolysis has not been established.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 52)", "text": "Use in Labor and Delivery Tocolysis Nursing Mothers Pediatric Use 2 Because of the potential for beta-agonist interference with uterine contractility, use of albuterol tablets for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk. Albuterol tablets have not been approved for the management of preterm labor. The benefit: risk ratio when albuterol tablets are administered for tocolysis has not been established. Serious adverse reactions, including maternal pulmonary edema, have been reported during or following treatment of premature labor with beta -agonists, including albuterol tablets.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 53)", "text": "Albuterol tablets have not been approved for the management of preterm labor. The benefit: risk ratio when albuterol tablets are administered for tocolysis has not been established. Serious adverse reactions, including maternal pulmonary edema, have been reported during or following treatment of premature labor with beta -agonists, including albuterol tablets. It is not known whether this drug is excreted in human milk.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 54)", "text": "The benefit: risk ratio when albuterol tablets are administered for tocolysis has not been established. Serious adverse reactions, including maternal pulmonary edema, have been reported during or following treatment of premature labor with beta -agonists, including albuterol tablets. It is not known whether this drug is excreted in human milk. Because of the potential for tumorigenicity shown for albuterol tablets in some animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "warnings", "section_title": "PRECAUTIONS SECTION (chunk 55)", "text": "Serious adverse reactions, including maternal pulmonary edema, have been reported during or following treatment of premature labor with beta -agonists, including albuterol tablets. It is not known whether this drug is excreted in human milk. Because of the potential for tumorigenicity shown for albuterol tablets in some animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Safety and effectiveness in children below 6 years of age have not been established.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 1)", "text": "In clinical trials, the most frequent adverse reactions to albuterol tablets were: Percent Incidence of Adverse Reactions Rare cases of urticaria, angioedema, rash, bronchospasm and oropharyngeal edema have been reported after the use of albuterol tablets.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 2)", "text": "In clinical trials, the most frequent adverse reactions to albuterol tablets were: Percent Incidence of Adverse Reactions Rare cases of urticaria, angioedema, rash, bronchospasm and oropharyngeal edema have been reported after the use of albuterol tablets. In addition, albuterol tablets, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vomiting, vertigo, central nervous system stimulation, unusual taste, and drying or irritation of the oropharynx.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 3)", "text": "In clinical trials, the most frequent adverse reactions to albuterol tablets were: Percent Incidence of Adverse Reactions Rare cases of urticaria, angioedema, rash, bronchospasm and oropharyngeal edema have been reported after the use of albuterol tablets. In addition, albuterol tablets, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vomiting, vertigo, central nervous system stimulation, unusual taste, and drying or irritation of the oropharynx. The reactions are generally transient in nature, and it is usually not necessary to discontinue treatment with albuterol tablets.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 4)", "text": "In clinical trials, the most frequent adverse reactions to albuterol tablets were: Percent Incidence of Adverse Reactions Rare cases of urticaria, angioedema, rash, bronchospasm and oropharyngeal edema have been reported after the use of albuterol tablets. In addition, albuterol tablets, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vomiting, vertigo, central nervous system stimulation, unusual taste, and drying or irritation of the oropharynx. The reactions are generally transient in nature, and it is usually not necessary to discontinue treatment with albuterol tablets. In selected cases, however, dosage may be reduced temporarily; after the reaction has subsided, dosage should be increased in small increments to the optimal dosage.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 5)", "text": "In addition, albuterol tablets, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vomiting, vertigo, central nervous system stimulation, unusual taste, and drying or irritation of the oropharynx. The reactions are generally transient in nature, and it is usually not necessary to discontinue treatment with albuterol tablets. In selected cases, however, dosage may be reduced temporarily; after the reaction has subsided, dosage should be increased in small increments to the optimal dosage. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 6)", "text": "The reactions are generally transient in nature, and it is usually not necessary to discontinue treatment with albuterol tablets. In selected cases, however, dosage may be reduced temporarily; after the reaction has subsided, dosage should be increased in small increments to the optimal dosage. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 7)", "text": "In selected cases, however, dosage may be reduced temporarily; after the reaction has subsided, dosage should be increased in small increments to the optimal dosage. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Reaction Incidence Percent Central nervous system Nervousness 20% Tremor 20% Headache 7% Sleeplessness 2% Weakness 2% Dizziness 2% Drowsiness &lt;1% Restlessness &lt;1% Irritability &lt;1% Cardiovascular Tachycardia 5% Palpitations 5% Chest discomfort &lt;1% Flushing &lt;1% Musculoskeletal Muscle cramps 3% Gastrointestinal Nausea 2% Genitourinary Difficulty in micturition &lt;1%", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 2)", "text": "2 2 2 2 2 2 The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 3)", "text": "2 2 2 2 2 2 The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalemia may also occur.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 4)", "text": "2 2 2 2 2 2 The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalemia may also occur. As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of albuterol tablets.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 5)", "text": "2 2 2 2 2 2 The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalemia may also occur. As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of albuterol tablets. Treatment consists of discontinuation of albuterol tablets together with appropriate symptomatic therapy.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 6)", "text": "Hypokalemia may also occur. As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of albuterol tablets. Treatment consists of discontinuation of albuterol tablets together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 7)", "text": "As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of albuterol tablets. Treatment consists of discontinuation of albuterol tablets together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of albuterol tablets.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 8)", "text": "Treatment consists of discontinuation of albuterol tablets together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of albuterol tablets. The oral median lethal dose of albuterol sulfate in mice is greater than 2000 mg/kg (approximately 250 times the maximum recommended daily oral dose for adults on a mg/m basis, or, approximately 200 times the maximum recommended daily oral dose for children on a mg/m basis).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 9)", "text": "The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of albuterol tablets. The oral median lethal dose of albuterol sulfate in mice is greater than 2000 mg/kg (approximately 250 times the maximum recommended daily oral dose for adults on a mg/m basis, or, approximately 200 times the maximum recommended daily oral dose for children on a mg/m basis). In mature rats, the subcutaneous (sc) median lethal dose of albuterol sulfate is approximately 450 mg/kg (approximately 110 times the maximum recommended daily oral dose for adults on a mg/m basis, and approximately 90 times the maximum recommended daily oral dose for children on a mg/m basis).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 10)", "text": "There is insufficient evidence to determine if dialysis is beneficial for overdosage of albuterol tablets. The oral median lethal dose of albuterol sulfate in mice is greater than 2000 mg/kg (approximately 250 times the maximum recommended daily oral dose for adults on a mg/m basis, or, approximately 200 times the maximum recommended daily oral dose for children on a mg/m basis). In mature rats, the subcutaneous (sc) median lethal dose of albuterol sulfate is approximately 450 mg/kg (approximately 110 times the maximum recommended daily oral dose for adults on a mg/m basis, and approximately 90 times the maximum recommended daily oral dose for children on a mg/m basis). In small young rats, the subcutaneous median lethal dose is approximately 2000 mg/kg (approximately 500 times the maximum recommended daily oral dose for adults on a mg/m basis, or, approximately 400 times the maximum recommended daily oral dose for children on a mg/m basis).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 2)", "text": "Usual Dosage Adults and Children Over 12 Years of Age Children 6 to 12 Years of Age: Dosage Adjustment Adults and Children Over 12 Years of Age only Children 6 to 12 Years of Age Who Fail to Respond to the Initial Starting Dosage of 2 mg Four Times a Day Elderly Patients and Those Sensitive to Beta-adrenergic Stimulators The following dosages of albuterol tablets are expressed in terms of albuterol base.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 3)", "text": "Usual Dosage Adults and Children Over 12 Years of Age Children 6 to 12 Years of Age: Dosage Adjustment Adults and Children Over 12 Years of Age only Children 6 to 12 Years of Age Who Fail to Respond to the Initial Starting Dosage of 2 mg Four Times a Day Elderly Patients and Those Sensitive to Beta-adrenergic Stimulators The following dosages of albuterol tablets are expressed in terms of albuterol base. The usual starting dosage for adults and children 12 years and older is 2 or 4 mg three or four times a day.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 4)", "text": "Usual Dosage Adults and Children Over 12 Years of Age Children 6 to 12 Years of Age: Dosage Adjustment Adults and Children Over 12 Years of Age only Children 6 to 12 Years of Age Who Fail to Respond to the Initial Starting Dosage of 2 mg Four Times a Day Elderly Patients and Those Sensitive to Beta-adrenergic Stimulators The following dosages of albuterol tablets are expressed in terms of albuterol base. The usual starting dosage for adults and children 12 years and older is 2 or 4 mg three or four times a day. The usual starting dosage for children 6 to 12 years age is 2 mg three or four times a day.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 5)", "text": "Usual Dosage Adults and Children Over 12 Years of Age Children 6 to 12 Years of Age: Dosage Adjustment Adults and Children Over 12 Years of Age only Children 6 to 12 Years of Age Who Fail to Respond to the Initial Starting Dosage of 2 mg Four Times a Day Elderly Patients and Those Sensitive to Beta-adrenergic Stimulators The following dosages of albuterol tablets are expressed in terms of albuterol base. The usual starting dosage for adults and children 12 years and older is 2 or 4 mg three or four times a day. The usual starting dosage for children 6 to 12 years age is 2 mg three or four times a day. For adults and children 12 years and older, a dosage above 4 mg four times a day should be used when the patient fails to respond.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 6)", "text": "The usual starting dosage for adults and children 12 years and older is 2 or 4 mg three or four times a day. The usual starting dosage for children 6 to 12 years age is 2 mg three or four times a day. For adults and children 12 years and older, a dosage above 4 mg four times a day should be used when the patient fails to respond. If a favorable response does not occur with the 4 mg initial dosage, it should be cautiously increased stepwise up to a maximum of 8 mg four times a day as tolerated.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 7)", "text": "The usual starting dosage for children 6 to 12 years age is 2 mg three or four times a day. For adults and children 12 years and older, a dosage above 4 mg four times a day should be used when the patient fails to respond. If a favorable response does not occur with the 4 mg initial dosage, it should be cautiously increased stepwise up to a maximum of 8 mg four times a day as tolerated. For children from 6 to 12 years of age who fail to respond to the initial starting dosage of 2 mg four times a day, the dosage may be cautiously increased stepwise, but not to exceed 24 mg/day (given in divided doses).", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 8)", "text": "For adults and children 12 years and older, a dosage above 4 mg four times a day should be used when the patient fails to respond. If a favorable response does not occur with the 4 mg initial dosage, it should be cautiously increased stepwise up to a maximum of 8 mg four times a day as tolerated. For children from 6 to 12 years of age who fail to respond to the initial starting dosage of 2 mg four times a day, the dosage may be cautiously increased stepwise, but not to exceed 24 mg/day (given in divided doses). An initial dosage of 2 mg three or four times a day is recommended for elderly patients and for those with a history of unusual sensitivity to beta-adrenergic stimulators.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 9)", "text": "If a favorable response does not occur with the 4 mg initial dosage, it should be cautiously increased stepwise up to a maximum of 8 mg four times a day as tolerated. For children from 6 to 12 years of age who fail to respond to the initial starting dosage of 2 mg four times a day, the dosage may be cautiously increased stepwise, but not to exceed 24 mg/day (given in divided doses). An initial dosage of 2 mg three or four times a day is recommended for elderly patients and for those with a history of unusual sensitivity to beta-adrenergic stimulators. If adequate bronchodilation is not obtained, dosage may be increased gradually to as much as 8 mg three or four times a day.", "source": "DailyMed"}
{"drug_name": "Albuterol", "category": "dosage", "section_title": "DOSAGE & ADMINISTRATION SECTION (chunk 10)", "text": "For children from 6 to 12 years of age who fail to respond to the initial starting dosage of 2 mg four times a day, the dosage may be cautiously increased stepwise, but not to exceed 24 mg/day (given in divided doses). An initial dosage of 2 mg three or four times a day is recommended for elderly patients and for those with a history of unusual sensitivity to beta-adrenergic stimulators. If adequate bronchodilation is not obtained, dosage may be increased gradually to as much as 8 mg three or four times a day. The total daily dose should not exceed 32 mg in adults and children over 12 years and older.", "source": "DailyMed"}
{"drug_name": "Gabapentin", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 1)", "text": "Gabapentin tablets are indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy", "source": "DailyMed"}
{"drug_name": "Gabapentin", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 1)", "text": "• 600 mg: white, biconvex, elliptical, film-coated tablets, with deep break line on both sides and debossed with ‘D’ and ‘24’ on either side of the break line on one side and plain on other side. • 800 mg: white, biconvex, elliptical, film-coated tablets, with deep break line on both sides and debossed with ‘D’ and ‘25’ on either side of the break line on one side and plain on other side.", "source": "DailyMed"}
{"drug_name": "Gabapentin", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 1)", "text": "Gabapentin tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.", "source": "DailyMed"}
{"drug_name": "Gabapentin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Gabapentin", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 2)", "text": "The following serious adverse reactions are discussed in greater detail in other sections: Warnings and Precautions (5.1) [see ] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Warnings and Precautions (5.2) [see ] Anaphylaxis and Angioedema Warnings and Precautions (5.4) [see ] Somnolence/Sedation and Dizziness Warnings and Precautions (5.5 [see )] Suicidal Behavior and Ideation Warnings and Precautions (5.6) [see ] Increased Risk of Seizures and Other Adverse Reactions with Abrupt or Rapid Discontinuation Warnings and Precautions (5.7) [see ] Status Epilepticus Warnings and Precautions (5.8) [see ] Respiratory Depression Warnings and Precautions (5.9) [see ] Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age)", "source": "DailyMed"}
{"drug_name": "Gabapentin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "Signs of acute toxicity in animals included ataxia, labored breathing, ptosis, sedation, hypoactivity, or excitation. Acute oral overdoses of gabapentin have been reported. Symptoms have included double vision, tremor, slurred speech, drowsiness, altered mental status, dizziness, lethargy, and diarrhea.", "source": "DailyMed"}
{"drug_name": "Gabapentin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 2)", "text": "Signs of acute toxicity in animals included ataxia, labored breathing, ptosis, sedation, hypoactivity, or excitation. Acute oral overdoses of gabapentin have been reported. Symptoms have included double vision, tremor, slurred speech, drowsiness, altered mental status, dizziness, lethargy, and diarrhea. Fatal respiratory depression has been reported with gabapentin overdose, alone and in combination with other CNS depressants.", "source": "DailyMed"}
{"drug_name": "Gabapentin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 3)", "text": "Acute oral overdoses of gabapentin have been reported. Symptoms have included double vision, tremor, slurred speech, drowsiness, altered mental status, dizziness, lethargy, and diarrhea. Fatal respiratory depression has been reported with gabapentin overdose, alone and in combination with other CNS depressants. Gabapentin can be removed by hemodialysis.", "source": "DailyMed"}
{"drug_name": "Gabapentin", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 4)", "text": "Symptoms have included double vision, tremor, slurred speech, drowsiness, altered mental status, dizziness, lethargy, and diarrhea. Fatal respiratory depression has been reported with gabapentin overdose, alone and in combination with other CNS depressants. Gabapentin can be removed by hemodialysis. If overexposure occurs, call your poison control center at 1-800-222-1222.", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 1)", "text": "5.1 See Warnings and Precautions ( ) Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [ ].", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "indications", "section_title": "INDICATIONS & USAGE SECTION (chunk 1)", "text": "14 See Clinical Studies ( ) Sertraline hydrochloride tablets are indicated for the treatment of the following [ ]: • Major depressive disorder (MDD) • Obsessive-compulsive disorder (OCD) • Panic disorder (PD) • Posttraumatic stress disorder (PTSD) • Social anxiety disorder (SAD) • Premenstrual dysphoric disorder (PMDD)", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 1)", "text": "25 mg tablets: light green, film coated, elliptical shaped, scored on one side of the tablet and debossed with \"757\" on the other side.", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 1)", "text": "Sertraline hydrochloride tablets are contraindicated in patients: 5.2 7.1 See Warnings and Precautions ( ), Drug Interactions ( ) Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [ ]. 7.1 See Drug Interactions ( ) Taking pimozide [ ].", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 2)", "text": "Sertraline hydrochloride tablets are contraindicated in patients: 5.2 7.1 See Warnings and Precautions ( ), Drug Interactions ( ) Taking, or within 14 days of stopping, MAOIs, (including the MAOIs linezolid and intravenous methylene blue) because of an increased risk of serotonin syndrome [ ]. 7.1 See Drug Interactions ( ) Taking pimozide [ ]. 6.1 6.2 See Adverse Reactions ( , ) With known hypersensitivity to sertraline (e.g., anaphylaxis, angioedema) [ ].", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 1)", "text": "", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "side_effects", "section_title": "ADVERSE REACTIONS SECTION (chunk 2)", "text": "The following adverse reactions are described in more detail in other sections of the prescribing information: 4 [See Contraindications ( )] Hypersensitivity reactions to sertraline 4 [See Contraindications ( ) 12.2 , Clinical Pharmacology ( )] QTc prolongation and ventricular arrhythmias when taken with pimozide 5.1 [See Warnings and Precautions ( )] Suicidal thoughts and behaviors 4 5.2 7.1 [See Contraindications ( ), Warnings and Precautions ( ), Drug Interactions ( )] Serotonin syndrome 5.3 [See Warnings and Precautions ( )] Increased risk of bleeding 5.4) [See Warnings and Precautions ( ] Activation of mania/hypomania 5.5 [See Warnings and Precautions ( )] Discontinuation syndrome 5.6 [See Warnings and Precautions ( )] Seizures 5.7 [See Warnings and Precautions ( )] Angle-closure glaucoma 5.8 [See Warnings and Precautions ( )] Hyponatremia 5.11 [See Warnings and Precautions ( )] Sexual Dysfunction", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "The following have been reported with sertraline tablet overdosage: • Seizures, which may be delayed, and altered mental status including coma. • Cardiovascular toxicity, which may be delayed, including QRS and QTc interval prolongation. Hypertension most commonly seen, but rarely can see hypotension alone or with co-ingestants including alcohol.", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 2)", "text": "The following have been reported with sertraline tablet overdosage: • Seizures, which may be delayed, and altered mental status including coma. • Cardiovascular toxicity, which may be delayed, including QRS and QTc interval prolongation. Hypertension most commonly seen, but rarely can see hypotension alone or with co-ingestants including alcohol. • Serotonin syndrome (patients with a multiple drug overdosage with other proserotonergic drugs may have a higher risk).", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 3)", "text": "• Cardiovascular toxicity, which may be delayed, including QRS and QTc interval prolongation. Hypertension most commonly seen, but rarely can see hypotension alone or with co-ingestants including alcohol. • Serotonin syndrome (patients with a multiple drug overdosage with other proserotonergic drugs may have a higher risk). Gastrointestinal decontamination with activated charcoal should be considered in patients who present early after a sertraline overdose.", "source": "DailyMed"}
{"drug_name": "Sertraline", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 4)", "text": "Hypertension most commonly seen, but rarely can see hypotension alone or with co-ingestants including alcohol. • Serotonin syndrome (patients with a multiple drug overdosage with other proserotonergic drugs may have a higher risk). Gastrointestinal decontamination with activated charcoal should be considered in patients who present early after a sertraline overdose. Consider contacting a Poison Center (1-800-221-2222) or a medical toxicologist for additional overdosage management recommendations.", "source": "DailyMed"}
{"drug_name": "Losartan", "category": "warnings", "section_title": "BOXED WARNING SECTION (chunk 1)", "text": "When pregnancy is detected, discontinue losartan potassium tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. [see Warnings and Precautions (5.1) ].", "source": "DailyMed"}
{"drug_name": "Losartan", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 1)", "text": "Losartan potassium tablets, 25 mg are white to off white, film coated, oval shaped tablets debossed with \"I16\" on one side and plain on other side. Losartan potassium tablets, 50 mg are white to off white, film coated, oval shaped scored tablets debossed with \"I\" and \"17\" on either side of the score line on one side and plain on other side.", "source": "DailyMed"}
{"drug_name": "Losartan", "category": "dosage", "section_title": "DOSAGE FORMS & STRENGTHS SECTION (chunk 2)", "text": "Losartan potassium tablets, 25 mg are white to off white, film coated, oval shaped tablets debossed with \"I16\" on one side and plain on other side. Losartan potassium tablets, 50 mg are white to off white, film coated, oval shaped scored tablets debossed with \"I\" and \"17\" on either side of the score line on one side and plain on other side. Losartan potassium tablets, 100 mg, are white to off white, film coated, oval shaped tablets debossed with \"I18\" on one side and plain on other side.", "source": "DailyMed"}
{"drug_name": "Losartan", "category": "contraindications", "section_title": "CONTRAINDICATIONS SECTION (chunk 1)", "text": "Losartan potassium tablets, are contraindicated: In patients who are hypersensitive to any component of this product. For coadministration with aliskiren in patients with diabetes.", "source": "DailyMed"}
{"drug_name": "Losartan", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 1)", "text": "2 Significant lethality was observed in mice and rats after oral administration of 1000 mg/kg and 2000 mg/kg, respectively, about 44 and 170 times the maximum recommended human dose on a mg/m basis. Limited data are available in regard to overdosage in humans.", "source": "DailyMed"}
{"drug_name": "Losartan", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 2)", "text": "2 Significant lethality was observed in mice and rats after oral administration of 1000 mg/kg and 2000 mg/kg, respectively, about 44 and 170 times the maximum recommended human dose on a mg/m basis. Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.", "source": "DailyMed"}
{"drug_name": "Losartan", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 3)", "text": "2 Significant lethality was observed in mice and rats after oral administration of 1000 mg/kg and 2000 mg/kg, respectively, about 44 and 170 times the maximum recommended human dose on a mg/m basis. Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted.", "source": "DailyMed"}
{"drug_name": "Losartan", "category": "overdosage", "section_title": "OVERDOSAGE SECTION (chunk 4)", "text": "Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Neither losartan nor its active metabolite can be removed by hemodialysis.", "source": "DailyMed"}
